{
  "usdmVersion": "4.0",
  "generatedAt": "2026-01-06T00:37:10.943890",
  "generator": "Protocol2USDM v6.5.0",
  "study": {
    "id": "239d198f-0e0a-4762-95b9-ed8c84937713",
    "instanceType": "Study",
    "versions": [
      {
        "id": "5e6f76c4-51de-4bc2-ab26-915ce59fbf9c",
        "instanceType": "StudyVersion",
        "versionIdentifier": "1.0",
        "studyDesigns": [
          {
            "id": "1de2510a-c2c8-4873-b761-fd912be866fb",
            "name": "Study Design",
            "rationale": "Protocol-defined study design for investigating efficacy and safety",
            "instanceType": "InterventionalStudyDesign",
            "blindingSchema": {
              "id": "645d67fa-0669-4db6-bc0d-5c51e7f29027",
              "standardCode": {
                "id": "4d31c18a-36b8-4339-a40d-45d6113bb957",
                "code": "Double Blind",
                "codeSystem": "http://www.cdisc.org",
                "codeSystemVersion": "2024-09-27",
                "decode": "Double Blind",
                "instanceType": "Code"
              },
              "instanceType": "AliasCode"
            },
            "randomizationType": {
              "code": "Randomized"
            },
            "arms": [
              {
                "id": "25c3a63c-e1de-47ab-81b9-f5ba15be73d6",
                "name": "Arm A: Palbociclib + Fulvestrant",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Patients receive palbociclib 125 mg/day orally for 3 weeks followed by 1 week off, plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and every 28 days thereafter.",
                "type": {
                  "id": "C174266",
                  "code": "C174266",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Investigational Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "8aabd708-7e14-4b65-ac62-1c1608dc0170",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              },
              {
                "id": "cb7f8cf8-8944-4bc0-91fd-3c805a6aef50",
                "name": "Arm B: Placebo + Fulvestrant",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Patients receive placebo orally daily for 3 weeks followed by 1 week off, plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and every 28 days thereafter.",
                "type": {
                  "id": "C174268",
                  "code": "C174268",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.12e",
                  "decode": "Placebo Control Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "c4b2fe50-085f-410d-ba11-b85558327d1f",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              }
            ],
            "studyCohorts": [
              {
                "id": "f8fd0fd7-4186-4160-912a-0ee66334464b",
                "name": "Pre-/peri-menopausal women",
                "instanceType": "StudyCohort",
                "characteristic": "Patients who are pre- or peri-menopausal at study entry and receive the LHRH agonist goserelin in addition to their assigned randomized treatment."
              },
              {
                "id": "a1110c4c-7bd0-48fa-8da1-b6ae4c1cc28d",
                "name": "Post-menopausal women",
                "instanceType": "StudyCohort",
                "characteristic": "Patients who are post-menopausal at study entry."
              }
            ],
            "studyCells": [
              {
                "id": "9d8522e9-795e-4a78-be13-86e34f75b839",
                "armId": "25c3a63c-e1de-47ab-81b9-f5ba15be73d6",
                "epochId": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "20fcd2bf-73be-4484-b9fe-be22940e75a4",
                "armId": "25c3a63c-e1de-47ab-81b9-f5ba15be73d6",
                "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "adf80abf-9932-41d9-8e4b-b8e0cb635807",
                "armId": "25c3a63c-e1de-47ab-81b9-f5ba15be73d6",
                "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "5bc49c56-92e9-4296-9bdf-0f3de2394b97",
                "armId": "25c3a63c-e1de-47ab-81b9-f5ba15be73d6",
                "epochId": "41864c37-b04e-42f6-a269-8894768c6064",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "121af05d-a61b-45d7-94b0-bf9ed372cd8f",
                "armId": "cb7f8cf8-8944-4bc0-91fd-3c805a6aef50",
                "epochId": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "7e234335-5d19-4726-a0d7-b039c92c173b",
                "armId": "cb7f8cf8-8944-4bc0-91fd-3c805a6aef50",
                "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "1ec75e4c-165e-4d7a-af44-56b7f3532794",
                "armId": "cb7f8cf8-8944-4bc0-91fd-3c805a6aef50",
                "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "202f6cda-775d-4b08-9c23-2f6de0a04751",
                "armId": "cb7f8cf8-8944-4bc0-91fd-3c805a6aef50",
                "epochId": "41864c37-b04e-42f6-a269-8894768c6064",
                "elementIds": [],
                "instanceType": "StudyCell"
              }
            ],
            "eligibilityCriteria": [
              {
                "id": "7c77477a-bc70-4086-9da9-89701e28bcea",
                "identifier": "1",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "abd9a584-aa1c-4151-8999-4a5276c32c5c",
                "instanceType": "EligibilityCriterion",
                "name": "Age and Menopausal Status",
                "nextId": "08a23987-c169-44dd-aadd-9b9a517f52fd"
              },
              {
                "id": "08a23987-c169-44dd-aadd-9b9a517f52fd",
                "identifier": "2",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "85892ace-8e94-4e70-a835-23f4e7dadf87",
                "instanceType": "EligibilityCriterion",
                "name": "Diagnosis of Breast Cancer",
                "previousId": "7c77477a-bc70-4086-9da9-89701e28bcea",
                "nextId": "99d6f05c-d6bb-49a9-ad3a-e461b86d0e6d"
              },
              {
                "id": "99d6f05c-d6bb-49a9-ad3a-e461b86d0e6d",
                "identifier": "3",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "b437645e-dd37-4628-9467-e86566280414",
                "instanceType": "EligibilityCriterion",
                "name": "ER/PR Status",
                "previousId": "08a23987-c169-44dd-aadd-9b9a517f52fd",
                "nextId": "98a3a43c-2fe5-4c3e-8426-533b0dabb04b"
              },
              {
                "id": "98a3a43c-2fe5-4c3e-8426-533b0dabb04b",
                "identifier": "4",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "88d685db-073b-4acd-b01d-aae8fd88ca57",
                "instanceType": "EligibilityCriterion",
                "name": "HER2 Status",
                "previousId": "99d6f05c-d6bb-49a9-ad3a-e461b86d0e6d",
                "nextId": "a1901b50-5467-45cf-a074-c831ae772e69"
              },
              {
                "id": "a1901b50-5467-45cf-a074-c831ae772e69",
                "identifier": "5",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "081b7e2f-537c-4492-994c-dc5bce0bcf38",
                "instanceType": "EligibilityCriterion",
                "name": "Prior Therapy Requirements",
                "previousId": "98a3a43c-2fe5-4c3e-8426-533b0dabb04b",
                "nextId": "1f25dee0-c678-4703-aeda-acf94a3332e5"
              },
              {
                "id": "1f25dee0-c678-4703-aeda-acf94a3332e5",
                "identifier": "6",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "f0cdd571-36d7-477a-bfd1-ad9c28328dcc",
                "instanceType": "EligibilityCriterion",
                "name": "Tumor Tissue Sample Provision",
                "previousId": "a1901b50-5467-45cf-a074-c831ae772e69",
                "nextId": "0d28bcbd-7045-48c4-a9b0-d075cf4f23e7"
              },
              {
                "id": "0d28bcbd-7045-48c4-a9b0-d075cf4f23e7",
                "identifier": "7",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "e0481db4-9a40-4d2d-a55c-9f51a5f0193d",
                "instanceType": "EligibilityCriterion",
                "name": "Disease Measurability",
                "previousId": "1f25dee0-c678-4703-aeda-acf94a3332e5",
                "nextId": "75153f07-c05f-4ffb-bf00-b8e916defcb6"
              },
              {
                "id": "75153f07-c05f-4ffb-bf00-b8e916defcb6",
                "identifier": "8",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "8dab0893-04cb-40ca-989a-81bf3c570511",
                "instanceType": "EligibilityCriterion",
                "name": "ECOG Performance Status",
                "previousId": "0d28bcbd-7045-48c4-a9b0-d075cf4f23e7",
                "nextId": "1bb814a2-86d3-4382-9936-c9ed51ac7057"
              },
              {
                "id": "1bb814a2-86d3-4382-9936-c9ed51ac7057",
                "identifier": "9",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9c1321e0-237d-49dc-9830-28d7f2f1f350",
                "instanceType": "EligibilityCriterion",
                "name": "Adequate Organ and Marrow Function",
                "previousId": "75153f07-c05f-4ffb-bf00-b8e916defcb6"
              }
            ],
            "population": {
              "id": "1e6c0cfc-3cb6-45e7-9fd9-ddcd9dbbca47",
              "name": "Study Population",
              "includesHealthySubjects": false,
              "criterionIds": [
                "7c77477a-bc70-4086-9da9-89701e28bcea",
                "08a23987-c169-44dd-aadd-9b9a517f52fd",
                "99d6f05c-d6bb-49a9-ad3a-e461b86d0e6d",
                "98a3a43c-2fe5-4c3e-8426-533b0dabb04b",
                "a1901b50-5467-45cf-a074-c831ae772e69",
                "1f25dee0-c678-4703-aeda-acf94a3332e5",
                "0d28bcbd-7045-48c4-a9b0-d075cf4f23e7",
                "75153f07-c05f-4ffb-bf00-b8e916defcb6",
                "1bb814a2-86d3-4382-9936-c9ed51ac7057"
              ],
              "instanceType": "StudyDesignPopulation",
              "description": "Target population defined by eligibility criteria"
            },
            "objectives": [
              {
                "id": "0ed3cb79-5878-4768-af19-ad3f734f16ef",
                "name": "Primary Efficacy Objective",
                "text": "To demonstrate the superiority of palbociclib in combination with fulvestrant (with or without goserelin) over fulvestrant alone (with or without goserelin) in prolonging investigator-assessed PFS in women with HR+/HER2-negative metastatic breast cancer whose disease has progressed on prior endocrine therapy.",
                "level": {
                  "id": "C85826",
                  "code": "C85826",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Primary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "5832fdc2-d637-4f0c-b52f-823b4d8550df"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "b2d40cdb-19b1-45cf-aaa0-378071b17d53",
                "name": "Tumor Control Objective",
                "text": "To compare measures of tumor control between the treatment arms.",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "37dc2644-5916-47c3-bf41-9f11ba06bfec",
                  "02809558-7f76-4dcb-add2-cc63ae318e16",
                  "27b0e2be-415a-4901-9a6d-adfa749a1724",
                  "b7d94d70-dffe-4a23-99dc-bd060604bc2d",
                  "b6f4f8a9-93ac-45d4-8b5f-6c96a3eba4b5"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "e51452ad-bd4e-41d6-b168-d901a613a60c",
                "name": "Safety and Tolerability Objective",
                "text": "To compare safety and tolerability between the treatment arms.",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "61c48f41-32c8-49f5-8f3a-aaa70b40e02d"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "e6740517-5ed5-41dd-98b5-3d9d074cde3c",
                "name": "Palbociclib Pharmacokinetic Objective",
                "text": "To evaluate trough concentrations of palbociclib when given in combination with fulvestrant or fulvestrant plus goserelin, compared to historical palbociclib data.",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "6b045ec5-33b5-4c76-9a95-3027d6f214a6"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "8d371b1a-e13f-436a-89ee-5cbcb0245660",
                "name": "Fulvestrant and Goserelin Pharmacokinetic Objective",
                "text": "To compare fulvestrant and goserelin trough concentrations when given in combination with palbociclib to those when given without palbociclib.",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "6b045ec5-33b5-4c76-9a95-3027d6f214a6"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "963cb1d3-8c9d-4e51-ba82-d28283e93678",
                "name": "Exposure-Response Objective",
                "text": "To explore correlations between palbociclib exposures and efficacy/safety findings in this patient population.",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "6b045ec5-33b5-4c76-9a95-3027d6f214a6"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "0aec14cb-45eb-437f-bce0-384bdc8a68a8",
                "name": "Patient Reported Outcomes Objective",
                "text": "To compare Patient Reported Outcomes measures between treatment arms.",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "a81a8011-ed06-46fd-bfa6-722d4641fa87"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "e1537bb7-1bd9-4998-80df-e51a351c5a26",
                "name": "Biomarker Objective",
                "text": "To characterize alterations in genes, proteins, and ribonucleic acids (RNAs) relevant to the cell cycle, drug targets, tumor sensitivity and/or resistance.",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "8c674ada-13b1-4757-a9cb-b3dd55617ede"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "a8793f86-0a85-47b4-aca8-0e3083f88529",
                "name": "Subgroup Analysis Objective",
                "text": "To conduct subgroup analysis for primary and secondary endpoints in stratified groups.",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [],
                "instanceType": "Objective"
              }
            ],
            "endpoints": [
              {
                "id": "5832fdc2-d637-4f0c-b52f-823b4d8550df",
                "name": "Progression-Free Survival (PFS)",
                "text": "Progression-Free Survival (PFS) as assessed by the Investigator.",
                "level": {
                  "id": "C98772",
                  "code": "C98772",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Primary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "37dc2644-5916-47c3-bf41-9f11ba06bfec",
                "name": "Overall Survival (OS)",
                "text": "Overall Survival (OS).",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "02809558-7f76-4dcb-add2-cc63ae318e16",
                "name": "Survival Probabilities",
                "text": "1-year, 2-year, and 3-year survival probabilities.",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "27b0e2be-415a-4901-9a6d-adfa749a1724",
                "name": "Objective Response (OR)",
                "text": "Objective Response (OR): Complete Response (CR) or Partial Response (PR).",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "b7d94d70-dffe-4a23-99dc-bd060604bc2d",
                "name": "Duration of Response (DR)",
                "text": "Duration of Response (DR).",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "b6f4f8a9-93ac-45d4-8b5f-6c96a3eba4b5",
                "name": "Clinical Benefit Response (CBR)",
                "text": "Clinical Benefit Response (CBR): CR or PR or Stable Disease (SD) ≥24 weeks.",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "61c48f41-32c8-49f5-8f3a-aaa70b40e02d",
                "name": "Adverse Events and Laboratory Abnormalities",
                "text": "Type, incidence, severity (as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.0), seriousness and relationship to study medications of Adverse Events (AEs) and any laboratory abnormalities.",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "6b045ec5-33b5-4c76-9a95-3027d6f214a6",
                "name": "Trough Plasma Concentrations",
                "text": "Trough plasma concentration of palbociclib, fulvestrant and goserelin (if applicable) in the subgroup of approximately 40 patients included in the initial safety review.",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacokinetic"
              },
              {
                "id": "a81a8011-ed06-46fd-bfa6-722d4641fa87",
                "name": "Patient Reported Outcomes (PRO)",
                "text": "PRO endpoints such as global quality of life symptoms and functioning assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Instrument (EORTC QLQ-C30) and European Organisation for Research and Treatment of Cancer Breast Cancer Module (EORTC QLQ-BR23) and Dimension Health State EuroQoL Score (EQ-5D)and time to deterioration (TTD) in pain endpoint.",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "QualityOfLife"
              },
              {
                "id": "8c674ada-13b1-4757-a9cb-b3dd55617ede",
                "name": "Tumor Tissue Biomarkers",
                "text": "Tumor tissue biomarkers, including genes (eg, copy numbers of CCND1 and CDKN2A, PIK3CA mutations), proteins (eg, Ki67, pRb, CCNE1), and RNA expression (eg, cdk4, cdk6).",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Biomarker"
              }
            ],
            "scheduleTimelines": [
              {
                "id": "397d7263-c38f-4cdb-bd77-929d721a2e4a",
                "name": "Main Schedule Timeline",
                "mainTimeline": true,
                "instanceType": "ScheduleTimeline",
                "entryCondition": "Subject enrolled in study",
                "entryId": "3beb9bb4-d09b-4d2d-897e-cebd5c0b23aa",
                "instances": [
                  {
                    "id": "3beb9bb4-d09b-4d2d-897e-cebd5c0b23aa",
                    "activityIds": [
                      "1c8ab8e3-9bf1-4a32-94df-c9a08d35b4b9"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Informed Consent @ Screening",
                    "epochId": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                    "encounterId": "74bdbadd-aa09-4208-a509-0aebe4dae00a"
                  },
                  {
                    "id": "6445feae-1be8-41d4-ba24-b3fa997c3255",
                    "activityIds": [
                      "01b7bf28-c38b-49a6-bc3b-4ec225bcdcfa"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Medical/Oncological History @ Screening",
                    "epochId": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                    "encounterId": "74bdbadd-aa09-4208-a509-0aebe4dae00a"
                  },
                  {
                    "id": "d536aef6-1a3b-45bd-9b23-d57f0a1fd227",
                    "activityIds": [
                      "a182ec73-3d13-48bc-81e3-855d47575ade"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Baseline Signs/Symptoms @ Cycles 1 and 2, Day 1b",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "b74a25da-ed1c-4b8d-bc6f-72ed3f131a0d",
                    "timingId": "d2a9ea43-a847-4336-b993-0db96ded89a5"
                  },
                  {
                    "id": "12ee91e9-6710-4b3f-814c-a3ac4b906199",
                    "activityIds": [
                      "ad6734e2-69b7-421e-9efb-6e475eff2803"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Physical Examination/Vital Signs @ Screening",
                    "epochId": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                    "encounterId": "74bdbadd-aa09-4208-a509-0aebe4dae00a"
                  },
                  {
                    "id": "4cad7a77-f873-4a62-a3c4-616e77c9693d",
                    "activityIds": [
                      "ad6734e2-69b7-421e-9efb-6e475eff2803"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Physical Examination/Vital Signs @ Cycles 1 and 2, Day 1b",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "b74a25da-ed1c-4b8d-bc6f-72ed3f131a0d",
                    "timingId": "d2a9ea43-a847-4336-b993-0db96ded89a5"
                  },
                  {
                    "id": "ceb890c0-0fb4-4042-a19c-66bf2d05470e",
                    "activityIds": [
                      "ad6734e2-69b7-421e-9efb-6e475eff2803"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Physical Examination/Vital Signs @ Cycles ≥3, Day 1",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "42f90da7-2951-4f49-8bec-d3d72deb3852",
                    "timingId": "d2a9ea43-a847-4336-b993-0db96ded89a5"
                  },
                  {
                    "id": "800ff26d-b655-4a6b-8586-399e68676b8c",
                    "activityIds": [
                      "ad6734e2-69b7-421e-9efb-6e475eff2803"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Physical Examination/Vital Signs @ End of Treatment/Withdrawal",
                    "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                    "encounterId": "e66624fc-2a93-4986-9ce6-ccb06bacb3de"
                  },
                  {
                    "id": "8d904bc9-6d68-4387-97d3-da329414cf10",
                    "activityIds": [
                      "f641adf8-1e52-489c-b2df-6cb5e6c3f01d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Ophthalmic Examination @ Screening",
                    "epochId": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                    "encounterId": "74bdbadd-aa09-4208-a509-0aebe4dae00a"
                  },
                  {
                    "id": "877d1676-7ab7-4a3b-8ff3-2f110db7887e",
                    "activityIds": [
                      "f641adf8-1e52-489c-b2df-6cb5e6c3f01d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Ophthalmic Examination @ Cycles ≥3, Day 1",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "42f90da7-2951-4f49-8bec-d3d72deb3852",
                    "timingId": "d2a9ea43-a847-4336-b993-0db96ded89a5"
                  },
                  {
                    "id": "c31d488a-7aa3-43e5-a992-33e7b561da25",
                    "activityIds": [
                      "f641adf8-1e52-489c-b2df-6cb5e6c3f01d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Ophthalmic Examination @ End of Treatment/Withdrawal",
                    "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                    "encounterId": "e66624fc-2a93-4986-9ce6-ccb06bacb3de"
                  },
                  {
                    "id": "65631f25-eb76-424c-ad81-1d6482ec4aa0",
                    "activityIds": [
                      "5fe39aa8-35ef-4f6b-9dd9-192c9328dab1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ECOG Performance Status @ Screening",
                    "epochId": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                    "encounterId": "74bdbadd-aa09-4208-a509-0aebe4dae00a"
                  },
                  {
                    "id": "24a17b2f-8268-4eb0-ad5f-1752a0132531",
                    "activityIds": [
                      "5fe39aa8-35ef-4f6b-9dd9-192c9328dab1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ECOG Performance Status @ Cycles 1 and 2, Day 1b",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "b74a25da-ed1c-4b8d-bc6f-72ed3f131a0d",
                    "timingId": "d2a9ea43-a847-4336-b993-0db96ded89a5"
                  },
                  {
                    "id": "c1fa8a64-347d-43b8-9786-e8978c4ac86e",
                    "activityIds": [
                      "5fe39aa8-35ef-4f6b-9dd9-192c9328dab1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ECOG Performance Status @ Cycles ≥3, Day 1",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "42f90da7-2951-4f49-8bec-d3d72deb3852",
                    "timingId": "d2a9ea43-a847-4336-b993-0db96ded89a5"
                  },
                  {
                    "id": "3d836cc3-dc09-48cc-a281-88a0e1bbef74",
                    "activityIds": [
                      "5fe39aa8-35ef-4f6b-9dd9-192c9328dab1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ECOG Performance Status @ End of Treatment/Withdrawal",
                    "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                    "encounterId": "e66624fc-2a93-4986-9ce6-ccb06bacb3de"
                  },
                  {
                    "id": "b5528cba-847b-4f73-a9b3-7dd2c0a35979",
                    "activityIds": [
                      "a49fde53-9ccc-49a4-841c-cdd00c72bfe4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Hematology @ Screening",
                    "epochId": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                    "encounterId": "74bdbadd-aa09-4208-a509-0aebe4dae00a"
                  },
                  {
                    "id": "81d8838a-8c0b-46e9-94f7-a5ca42436afc",
                    "activityIds": [
                      "a49fde53-9ccc-49a4-841c-cdd00c72bfe4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Hematology @ Cycles 1 and 2, Day 1b",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "b74a25da-ed1c-4b8d-bc6f-72ed3f131a0d",
                    "timingId": "d2a9ea43-a847-4336-b993-0db96ded89a5"
                  },
                  {
                    "id": "5ac3e0cb-32f9-49b6-ad79-5a5de66b2e42",
                    "activityIds": [
                      "a49fde53-9ccc-49a4-841c-cdd00c72bfe4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Hematology @ Cycles 1 and 2, Day 15",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "f9d3d083-b878-4180-ac99-583d6ebd0945",
                    "timingId": "e151a502-1dea-4539-ab88-787527b499af"
                  },
                  {
                    "id": "91d304a9-d523-47a6-8d1b-37ca78a4985d",
                    "activityIds": [
                      "a49fde53-9ccc-49a4-841c-cdd00c72bfe4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Hematology @ Cycles ≥3, Day 1",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "42f90da7-2951-4f49-8bec-d3d72deb3852",
                    "timingId": "d2a9ea43-a847-4336-b993-0db96ded89a5"
                  },
                  {
                    "id": "bad92828-725c-41ce-a136-46dfd8a45e3d",
                    "activityIds": [
                      "a49fde53-9ccc-49a4-841c-cdd00c72bfe4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Hematology @ End of Treatment/Withdrawal",
                    "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                    "encounterId": "e66624fc-2a93-4986-9ce6-ccb06bacb3de"
                  },
                  {
                    "id": "71d2e29f-473b-463f-ab76-ac45cf69dbfc",
                    "activityIds": [
                      "888aac34-03db-4777-9e71-0c3308e4a6db"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood Chemistry @ Screening",
                    "epochId": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                    "encounterId": "74bdbadd-aa09-4208-a509-0aebe4dae00a"
                  },
                  {
                    "id": "b3d8f40a-2e77-495d-9a32-d4b6086eb550",
                    "activityIds": [
                      "888aac34-03db-4777-9e71-0c3308e4a6db"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood Chemistry @ Cycles 1 and 2, Day 1b",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "b74a25da-ed1c-4b8d-bc6f-72ed3f131a0d",
                    "timingId": "d2a9ea43-a847-4336-b993-0db96ded89a5"
                  },
                  {
                    "id": "19520003-8bb5-4571-858d-39db8c53be2f",
                    "activityIds": [
                      "888aac34-03db-4777-9e71-0c3308e4a6db"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood Chemistry @ Cycles ≥3, Day 1",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "42f90da7-2951-4f49-8bec-d3d72deb3852",
                    "timingId": "d2a9ea43-a847-4336-b993-0db96ded89a5"
                  },
                  {
                    "id": "378947ed-477e-4f44-9089-d6b9fabd6fd6",
                    "activityIds": [
                      "888aac34-03db-4777-9e71-0c3308e4a6db"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood Chemistry @ End of Treatment/Withdrawal",
                    "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                    "encounterId": "e66624fc-2a93-4986-9ce6-ccb06bacb3de"
                  },
                  {
                    "id": "a89b7fd4-2aed-4bf0-889e-6495a2320708",
                    "activityIds": [
                      "bb3e1c27-db73-4aba-a5bb-089151998e24"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Pregnancy test, serum estradiol and FSH (if app... @ Screening",
                    "epochId": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                    "encounterId": "74bdbadd-aa09-4208-a509-0aebe4dae00a"
                  },
                  {
                    "id": "5af5bf8e-ef7d-4292-bc09-11dd25422981",
                    "activityIds": [
                      "70de1b01-73de-4401-b9de-dcd4d4960366"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "12-Lead ECG (in triplicate) @ Screening",
                    "epochId": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                    "encounterId": "74bdbadd-aa09-4208-a509-0aebe4dae00a"
                  },
                  {
                    "id": "28a85f18-3f60-4c8b-906f-b027eaca3b16",
                    "activityIds": [
                      "70de1b01-73de-4401-b9de-dcd4d4960366"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "12-Lead ECG (in triplicate) @ End of Treatment/Withdrawal",
                    "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                    "encounterId": "e66624fc-2a93-4986-9ce6-ccb06bacb3de"
                  },
                  {
                    "id": "ad7b3342-eb42-4e36-a9e5-0e529ed7ef03",
                    "activityIds": [
                      "3d661661-79e6-41f0-9234-21403843dc90"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "CT/MRI Scans of Chest, Abdomen, Pelvis, any cli... @ Screening",
                    "epochId": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                    "encounterId": "74bdbadd-aa09-4208-a509-0aebe4dae00a"
                  },
                  {
                    "id": "c3b6b4a5-ee3a-4711-a8fc-72a36edb2eb6",
                    "activityIds": [
                      "3d661661-79e6-41f0-9234-21403843dc90"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "CT/MRI Scans of Chest, Abdomen, Pelvis, any cli... @ End of Treatment/Withdrawal",
                    "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                    "encounterId": "e66624fc-2a93-4986-9ce6-ccb06bacb3de"
                  },
                  {
                    "id": "67b06003-2e8b-45d9-953a-19e70ab1fa61",
                    "activityIds": [
                      "3d661661-79e6-41f0-9234-21403843dc90"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "CT/MRI Scans of Chest, Abdomen, Pelvis, any cli... @ Post-Treatment Follow-Up",
                    "epochId": "41864c37-b04e-42f6-a269-8894768c6064",
                    "encounterId": "d4732051-f32d-480a-82e2-76c179924e18"
                  },
                  {
                    "id": "8c1f6011-4b7a-4d98-9aaa-93891f83410e",
                    "activityIds": [
                      "2702a55f-09cc-4d89-a596-59636826c9ab"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Radionuclide Bone Scan, Whole Body @ Screening",
                    "epochId": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                    "encounterId": "74bdbadd-aa09-4208-a509-0aebe4dae00a"
                  },
                  {
                    "id": "b58d53f3-e099-4aee-b675-75c440f5a4dc",
                    "activityIds": [
                      "2702a55f-09cc-4d89-a596-59636826c9ab"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Radionuclide Bone Scan, Whole Body @ End of Treatment/Withdrawal",
                    "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                    "encounterId": "e66624fc-2a93-4986-9ce6-ccb06bacb3de"
                  },
                  {
                    "id": "fbc095b5-a05f-4989-a572-1907fbc66537",
                    "activityIds": [
                      "2702a55f-09cc-4d89-a596-59636826c9ab"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Radionuclide Bone Scan, Whole Body @ Post-Treatment Follow-Up",
                    "epochId": "41864c37-b04e-42f6-a269-8894768c6064",
                    "encounterId": "d4732051-f32d-480a-82e2-76c179924e18"
                  },
                  {
                    "id": "7d26c113-75e7-4dd3-a2e7-fb74d0d680e3",
                    "activityIds": [
                      "2a4e371e-d2bb-4e3b-bee6-8fa6e50b476b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse Event Reporting @ Cycles 1 and 2, Day 1b",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "b74a25da-ed1c-4b8d-bc6f-72ed3f131a0d",
                    "timingId": "d2a9ea43-a847-4336-b993-0db96ded89a5"
                  },
                  {
                    "id": "b9005d62-710c-4f5b-a58e-eff3ccb4bfe1",
                    "activityIds": [
                      "2a4e371e-d2bb-4e3b-bee6-8fa6e50b476b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse Event Reporting @ Cycles 1 and 2, Day 15",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "f9d3d083-b878-4180-ac99-583d6ebd0945",
                    "timingId": "e151a502-1dea-4539-ab88-787527b499af"
                  },
                  {
                    "id": "7ffe5de5-23f6-4ddb-8a60-fc49aec4965f",
                    "activityIds": [
                      "2a4e371e-d2bb-4e3b-bee6-8fa6e50b476b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse Event Reporting @ Cycles ≥3, Day 1",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "42f90da7-2951-4f49-8bec-d3d72deb3852",
                    "timingId": "d2a9ea43-a847-4336-b993-0db96ded89a5"
                  },
                  {
                    "id": "e1804a96-237b-4bf2-a4c5-c9314a87f959",
                    "activityIds": [
                      "2a4e371e-d2bb-4e3b-bee6-8fa6e50b476b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse Event Reporting @ End of Treatment/Withdrawal",
                    "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                    "encounterId": "e66624fc-2a93-4986-9ce6-ccb06bacb3de"
                  },
                  {
                    "id": "e6af403c-a424-4711-bd82-c42e9ac163b9",
                    "activityIds": [
                      "2a4e371e-d2bb-4e3b-bee6-8fa6e50b476b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse Event Reporting @ Post-Treatment Follow-Up",
                    "epochId": "41864c37-b04e-42f6-a269-8894768c6064",
                    "encounterId": "d4732051-f32d-480a-82e2-76c179924e18"
                  },
                  {
                    "id": "84615588-83e1-4fb6-8a23-e462906bd68b",
                    "activityIds": [
                      "87e415cf-5b39-4ac4-bbe6-67994523e736"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "EuroQol-5D (EQ-5D) @ End of Treatment/Withdrawal",
                    "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                    "encounterId": "e66624fc-2a93-4986-9ce6-ccb06bacb3de"
                  },
                  {
                    "id": "88b7aa44-bda1-4bf9-9008-efaf10f7eb60",
                    "activityIds": [
                      "c4c108ae-8e2d-4f92-8fda-8a236dc55f1e"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "European Organization for Research and Treatmen... @ End of Treatment/Withdrawal",
                    "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                    "encounterId": "e66624fc-2a93-4986-9ce6-ccb06bacb3de"
                  },
                  {
                    "id": "5d12ead3-0e3a-416b-b6a7-a864368a6ebc",
                    "activityIds": [
                      "41614ee3-44e1-419e-b48a-194fc9554732"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "European Organisation for Research and Treatmen... @ End of Treatment/Withdrawal",
                    "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                    "encounterId": "e66624fc-2a93-4986-9ce6-ccb06bacb3de"
                  },
                  {
                    "id": "3b55e401-9a42-4651-827c-7acfb3acf4e1",
                    "activityIds": [
                      "10025ff1-e33a-4398-a558-3762a208567a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Survival Follow-up @ Post-Treatment Follow-Up",
                    "epochId": "41864c37-b04e-42f6-a269-8894768c6064",
                    "encounterId": "d4732051-f32d-480a-82e2-76c179924e18"
                  },
                  {
                    "id": "27f7e8b4-6869-4a3f-be54-8bcecf5e5bba",
                    "activityIds": [
                      "d752206b-47f8-4faf-9342-08f04d2ab1c1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Randomization @ Cycles 1 and 2, Day 1b",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "encounterId": "b74a25da-ed1c-4b8d-bc6f-72ed3f131a0d",
                    "timingId": "d2a9ea43-a847-4336-b993-0db96ded89a5"
                  },
                  {
                    "id": "ebb60687-ee14-4818-a0ac-1640512bee1e",
                    "name": "Anchor: FirstDose",
                    "description": "Time anchor for scheduling: FirstDose",
                    "encounterId": "b74a25da-ed1c-4b8d-bc6f-72ed3f131a0d",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "scheduledDay": 1
                  },
                  {
                    "id": "81c6f9fd-949d-4da3-ab8d-510336bdecdc",
                    "name": "Anchor: CycleStart",
                    "description": "Time anchor for scheduling: CycleStart",
                    "encounterId": "b74a25da-ed1c-4b8d-bc6f-72ed3f131a0d",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "scheduledDay": 1
                  },
                  {
                    "id": "86bb0228-0e57-4178-86bd-758ad28d7e49",
                    "name": "Anchor: InformedConsent",
                    "description": "Time anchor for scheduling: InformedConsent",
                    "encounterId": "b74a25da-ed1c-4b8d-bc6f-72ed3f131a0d",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "scheduledDay": 1
                  },
                  {
                    "id": "307b49ac-ca56-4f9d-b3fb-69e2b47929d3",
                    "name": "Anchor: Custom",
                    "description": "Time anchor for scheduling: Custom",
                    "encounterId": "b74a25da-ed1c-4b8d-bc6f-72ed3f131a0d",
                    "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "scheduledDay": 1
                  },
                  {
                    "id": "5e290bad-951d-45f8-b59e-246fd8910b42",
                    "name": "Auto-anchor for Fulvestrant Dosing Interval (Post-Cycle 1)",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance"
                  },
                  {
                    "id": "512b1d10-5376-4866-abcb-26c27c880cf2",
                    "name": "Auto-anchor for Palbociclib Dosing Schedule",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance"
                  },
                  {
                    "id": "a5d03641-a6aa-4fc1-a4c5-bebeb2c6f5fc",
                    "name": "Auto-anchor for Goserelin Pre-treatment Requirement",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance"
                  },
                  {
                    "id": "909e2f0c-c8b9-456e-ba54-03c2f690ef2b",
                    "name": "Auto-anchor for Goserelin Dosing Interval",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance"
                  },
                  {
                    "id": "b8d70b26-df8a-4dd9-ad63-c46eb03ef4de",
                    "name": "Auto-anchor for End of Treatment Visit",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance"
                  },
                  {
                    "id": "8e61f977-0187-4f05-b9e8-f848a04c8018",
                    "name": "Auto-anchor for Post-Treatment AE Follow-up",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance"
                  },
                  {
                    "id": "eec8aff2-3c2d-4a44-aef2-f47675a38578",
                    "name": "Auto-anchor for Survival Follow-up Interval",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance"
                  },
                  {
                    "id": "d285afa1-b8b9-4ff5-ac13-a620c8b54f61",
                    "name": "Auto-anchor for Ophthalmic Exam Schedule",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance"
                  },
                  {
                    "id": "c990d6a7-ee14-430a-9189-f3596f25d1af",
                    "name": "Auto-anchor for Blood Chemistry Interval (Cycles >=7)",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance"
                  },
                  {
                    "id": "d9bcbf02-70c0-48c9-b311-2b64cbabdbd5",
                    "name": "Auto-anchor for SAE Reporting Period",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance"
                  }
                ],
                "timings": [
                  {
                    "id": "979c3171-7f11-41cc-8afc-f5de7a5ebd04",
                    "name": "Screening Window",
                    "type": {
                      "id": "ee93b3f8-242c-4e46-95e5-e6d661056e42",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P28D",
                    "valueLabel": "Day 28",
                    "relativeToFrom": {
                      "id": "21d02ea1-5485-46e8-b49c-33e5e7a8347c",
                      "code": "C71154",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Randomization",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "3beb9bb4-d09b-4d2d-897e-cebd5c0b23aa",
                    "instanceType": "Timing",
                    "windowLower": "-P28D",
                    "windowUpper": "-P1D"
                  },
                  {
                    "id": "8bf7a36c-4916-4c88-8214-535543e8861b",
                    "name": "Cycle 1 Day 1 Visit Window",
                    "type": {
                      "id": "36f930d5-3be1-4552-ab5e-08f53753f867",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P1D",
                    "valueLabel": "Day 1",
                    "relativeToFrom": {
                      "id": "534e3d33-9515-46c3-bf67-ca59864e2c66",
                      "code": "C71154",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Randomization",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "d536aef6-1a3b-45bd-9b23-d57f0a1fd227",
                    "instanceType": "Timing",
                    "windowLower": "-P2D",
                    "windowUpper": "P2D"
                  },
                  {
                    "id": "e151a502-1dea-4539-ab88-787527b499af",
                    "name": "Cycle 1 Day 15 Visit Window",
                    "type": {
                      "id": "3e734550-af95-4a49-8d59-079495bc16df",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P15D",
                    "valueLabel": "Day 15",
                    "relativeToFrom": {
                      "id": "2f2283ea-9f0d-4eec-b467-9c6d3911d4ab",
                      "code": "C71153",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Study Start",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "d536aef6-1a3b-45bd-9b23-d57f0a1fd227",
                    "instanceType": "Timing",
                    "windowLower": "-P2D",
                    "windowUpper": "P2D"
                  },
                  {
                    "id": "000372ab-4494-4361-86ff-25b4900f48f9",
                    "name": "Cycles >=3 Day 1 Visit Window",
                    "type": {
                      "id": "c1d61a01-36c9-4fe8-9e8a-681782e18b74",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P1D",
                    "valueLabel": "Day 1",
                    "relativeToFrom": {
                      "id": "454dc3b6-bed5-43ab-aa80-a9ecd811102b",
                      "code": "C71153",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Study Start",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "d536aef6-1a3b-45bd-9b23-d57f0a1fd227",
                    "instanceType": "Timing",
                    "windowLower": "-P7D",
                    "windowUpper": "P7D"
                  },
                  {
                    "id": "d6a7b2b0-3cd5-430d-b76e-5f86a5e06f94",
                    "name": "Fulvestrant Dosing Interval (Post-Cycle 1)",
                    "type": {
                      "id": "e239d3d2-0d4d-4d4f-912e-093c3370e197",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P28D",
                    "valueLabel": "Day 28",
                    "relativeToFrom": {
                      "id": "10746921-2b48-4bfb-a267-9059f8ccb069",
                      "code": "C71157",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Previous Visit",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "5e290bad-951d-45f8-b59e-246fd8910b42",
                    "instanceType": "Timing",
                    "windowLower": "-P7D",
                    "windowUpper": "P7D"
                  },
                  {
                    "id": "3340cb34-a7f1-46c8-86fe-b45c27bc9531",
                    "name": "Palbociclib Dosing Schedule",
                    "type": {
                      "id": "ef4a5354-976a-499d-825e-b39ba41f8d18",
                      "code": "C71152",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Between",
                      "instanceType": "Code"
                    },
                    "value": "P21D",
                    "valueLabel": "Day 21",
                    "relativeToFrom": {
                      "id": "b2f74acf-5ebf-4baa-83d2-5b6b671630b6",
                      "code": "C71153",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Study Start",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "512b1d10-5376-4866-abcb-26c27c880cf2",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "94bf2465-4928-46ff-bef6-f52cd2820547",
                    "name": "Goserelin Pre-treatment Requirement",
                    "type": {
                      "id": "40fe2416-0ec3-497e-94e9-4b46b1c9d115",
                      "code": "C71149",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Before",
                      "instanceType": "Code"
                    },
                    "value": "P4W",
                    "valueLabel": "4 weeks",
                    "relativeToFrom": {
                      "id": "e1979c75-673a-414c-8b00-c64778279c30",
                      "code": "C71154",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Randomization",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "a5d03641-a6aa-4fc1-a4c5-bebeb2c6f5fc",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "f84d3663-8899-46e3-89b0-4481cea25988",
                    "name": "Goserelin Dosing Interval",
                    "type": {
                      "id": "d42e6d47-48a3-4b80-be41-3ca5b2e43061",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P28D",
                    "valueLabel": "Day 28",
                    "relativeToFrom": {
                      "id": "a9cf1b8a-3906-47a4-83ed-6d71efdc4b03",
                      "code": "C71153",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Study Start",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "909e2f0c-c8b9-456e-ba54-03c2f690ef2b",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "a9d8884d-25fc-42fd-a514-8a9e86e5933b",
                    "name": "End of Treatment Visit",
                    "type": {
                      "id": "4449cc76-58d8-4986-8cd1-68895f0e7741",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P4W",
                    "valueLabel": "4 weeks",
                    "relativeToFrom": {
                      "id": "bdac336d-c8eb-488b-9f11-81a2eb3282e7",
                      "code": "C71156",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Last Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "b8d70b26-df8a-4dd9-ad63-c46eb03ef4de",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "d6fe7099-55c6-4b52-b303-a17e8994e751",
                    "name": "Post-Treatment AE Follow-up",
                    "type": {
                      "id": "b062eb14-9a60-42b6-84ae-81c35d2ee45f",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P28D",
                    "valueLabel": "Day 28",
                    "relativeToFrom": {
                      "id": "d6c87234-b3c8-4dc0-b3ad-86f7329fd709",
                      "code": "C71156",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Last Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "8e61f977-0187-4f05-b9e8-f848a04c8018",
                    "instanceType": "Timing",
                    "windowLower": "-P7D",
                    "windowUpper": "P7D"
                  },
                  {
                    "id": "9bbd8a8b-daf2-4056-9db9-19b25c615699",
                    "name": "Survival Follow-up Interval",
                    "type": {
                      "id": "7ac86180-cb96-4787-ad6a-e5ff56085fbb",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P3D",
                    "valueLabel": "3 months",
                    "relativeToFrom": {
                      "id": "7944eec5-e9e9-4885-a689-578a8a247eb6",
                      "code": "C71156",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Last Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "eec8aff2-3c2d-4a44-aef2-f47675a38578",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "d2a9ea43-a847-4336-b993-0db96ded89a5",
                    "name": "Cycle 1 Day 1 Assessment Window",
                    "type": {
                      "id": "5e4c9542-3f9b-4668-9d15-36121d03814c",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P7D",
                    "valueLabel": "Day 7",
                    "relativeToFrom": {
                      "id": "a9a9cb06-e0b9-4c05-b3dd-d7e5180249f7",
                      "code": "C71154",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Randomization",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "d536aef6-1a3b-45bd-9b23-d57f0a1fd227",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "d9bf5086-64af-4138-bbea-76f30a0dd544",
                    "name": "Ophthalmic Exam Schedule",
                    "type": {
                      "id": "40fb62a3-6217-4f84-b292-b2699ae48f46",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P0D",
                    "valueLabel": "Ophthalmic Exam Schedule",
                    "relativeToFrom": {
                      "id": "36209be8-9e29-4bb0-9377-1aab518c5d19",
                      "code": "C71153",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Study Start",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "d285afa1-b8b9-4ff5-ac13-a620c8b54f61",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "2d286806-f31f-4b49-a720-ecd8579a8553",
                    "name": "Blood Chemistry Interval (Cycles >=7)",
                    "type": {
                      "id": "c9c26d94-8d8b-46dc-a774-0ec610890cb2",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P3D",
                    "valueLabel": "3 cycles",
                    "relativeToFrom": {
                      "id": "a547182e-44a9-47af-9a12-f20d6f84f2d3",
                      "code": "C71153",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Study Start",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "c990d6a7-ee14-430a-9189-f3596f25d1af",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "93a07834-e4d4-471f-a464-efc90bd31dc5",
                    "name": "SAE Reporting Period",
                    "type": {
                      "id": "d12d1fe4-e8ae-4161-81a0-dc973e67709f",
                      "code": "C71152",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Between",
                      "instanceType": "Code"
                    },
                    "value": "P0D",
                    "valueLabel": "SAE Reporting Period",
                    "relativeToFrom": {
                      "id": "e5788030-1a28-457a-bd1d-1de2f1c1b569",
                      "code": "C71153",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Study Start",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "d9bcbf02-70c0-48c9-b311-2b64cbabdbd5",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P0D"
                  }
                ],
                "exits": [
                  {
                    "id": "3466c3be-50f1-41e2-9ef1-f8a2fcc8c627",
                    "name": "Treatment Discontinuation Criteria",
                    "exitType": "Early Termination",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Criteria for discontinuing assigned study treatment."
                  },
                  {
                    "id": "ce2e24b2-b631-489a-9ea3-3c384e64ebd2",
                    "name": "Palbociclib Discontinuation for Delayed Recovery",
                    "exitType": "Early Termination",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Permanent discontinuation of palbociclib if recovery from toxicity takes too long."
                  },
                  {
                    "id": "1385f0ac-e846-4ec9-b255-b6fcdb009fd6",
                    "name": "Study Completion",
                    "exitType": "Completion",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Patient completes the study after finishing treatment and all follow-up."
                  }
                ]
              }
            ],
            "encounters": [
              {
                "id": "b74a25da-ed1c-4b8d-bc6f-72ed3f131a0d",
                "name": "Cycles 1 and 2, Day 1b",
                "instanceType": "Encounter",
                "type": {
                  "id": "643f26ee-ac30-4527-b62a-8d3fe80ecfc2",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                "extensionAttributes": [
                  {
                    "id": "fce5652b-97dd-4aa3-8674-0a6e79dd47b8",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "9d983a02-f0ef-4b4a-adeb-f42d7b8941cc",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "9737d96d-51ff-4ad3-a635-3c8980379e13",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 1
                  }
                ]
              },
              {
                "id": "42f90da7-2951-4f49-8bec-d3d72deb3852",
                "name": "Cycles ≥3, Day 1",
                "instanceType": "Encounter",
                "type": {
                  "id": "d804de68-b585-46f9-956a-770a1780490a",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                "extensionAttributes": [
                  {
                    "id": "091df2aa-bd73-47a2-a45a-6d6f9b6dd385",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "1dc01258-d44d-4443-8dce-e9e6e793eada",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "0c61dc11-445d-4793-9191-9e55e3a2aa24",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 1
                  }
                ]
              },
              {
                "id": "f9d3d083-b878-4180-ac99-583d6ebd0945",
                "name": "Cycles 1 and 2, Day 15",
                "instanceType": "Encounter",
                "type": {
                  "id": "2f783179-86de-4f5a-ae1b-a2ec624256f2",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                "extensionAttributes": [
                  {
                    "id": "b3683361-c813-429f-a7d7-4cd953c83fef",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "0afeb667-f8f2-458f-a4e3-deafa37ef2ec",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "1cdde8c2-f5e3-4266-99be-7a6e9ac2cb85",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 15
                  }
                ]
              },
              {
                "id": "e66624fc-2a93-4986-9ce6-ccb06bacb3de",
                "name": "End of Treatment/Withdrawal",
                "instanceType": "Encounter",
                "type": {
                  "id": "1f0650b2-8189-4d74-b0f7-743f02273f53",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Visit",
                  "instanceType": "Code"
                },
                "epochId": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                "extensionAttributes": [
                  {
                    "id": "a5738c2a-8ffd-4e76-8aa5-edc903e0f835",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "bff0c058-225b-4f28-ac5a-781490012090",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "d4732051-f32d-480a-82e2-76c179924e18",
                "name": "Post-Treatment Follow-Up",
                "instanceType": "Encounter",
                "type": {
                  "id": "82d65d92-0153-4c7f-a639-43c4b5ebb905",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Visit",
                  "instanceType": "Code"
                },
                "epochId": "41864c37-b04e-42f6-a269-8894768c6064",
                "extensionAttributes": [
                  {
                    "id": "bab82f03-8180-4533-8f31-fb58b48fe507",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "5f6eec93-9866-4ebf-9221-8b7b32499367",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "74bdbadd-aa09-4208-a509-0aebe4dae00a",
                "name": "Screening",
                "instanceType": "Encounter",
                "type": {
                  "id": "da89429f-e7f3-48a5-bdc8-d942b32c7210",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Visit",
                  "instanceType": "Code"
                },
                "epochId": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                "extensionAttributes": [
                  {
                    "id": "b11a05d3-d2f6-4421-bef0-6cd9acd6b489",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "d4f87221-eece-4baf-955a-da8e72b671d7",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "0ab67564-a665-449e-b12c-6a5688c9af5a",
                "name": "Visit",
                "instanceType": "Encounter",
                "type": {
                  "id": "65bd08a7-d2fd-4bea-8ad7-74dbe375bb53",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "de213bc9-e8a7-4399-b4d7-58954402a7fc",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "execution"
                  },
                  {
                    "id": "d2f96d8c-7b05-4466-be7b-0a4f569683ea",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              }
            ],
            "activities": [
              {
                "id": "1d685aa9-43e2-48b2-8331-95d77262c2ea",
                "name": "",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "de8d0938-a321-4b59-8917-087ef11e5889",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "execution"
                  },
                  {
                    "id": "06ba16c1-70d6-46b2-ba4b-7d5919735391",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "f0eb9de7-3fa0-4d06-bf3e-8e0e6eb8762e",
                    "url": "https://protocol2usdm.io/extensions/x-activityRepetitionId",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "rep_llm_1"
                  },
                  {
                    "id": "c2e66b2c-9645-400c-995b-b3e106024ef2",
                    "url": "https://protocol2usdm.io/extensions/x-activityTiming",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "{'frequency': None, 'interval': None, 'count': None}"
                  }
                ]
              },
              {
                "id": "70de1b01-73de-4401-b9de-dcd4d4960366",
                "name": "12-Lead ECG (in triplicate)",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "96c18cde-6a85-4cf6-9e57-7edd5e3c57ae",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "84260753-efdb-4c83-aee1-e0facdcf3f27",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "be1f2705-2877-4e02-bae8-89b015998c44",
                "name": "12-Lead Electrocardiogram",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "0cf5cb93-fccf-419e-8327-19d18cc0fa4c",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "c1099899-be59-4b6c-8c46-33d33bb03804",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "2a4e371e-d2bb-4e3b-bee6-8fa6e50b476b",
                "name": "Adverse Event Reporting",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "3b4ffdb9-dbd5-4a53-b322-e0f4500bfc7e",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "14ab794c-c108-46af-abdd-be2a30907e96",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  }
                ]
              },
              {
                "id": "a182ec73-3d13-48bc-81e3-855d47575ade",
                "name": "Baseline Signs/Symptoms",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "0e913aa9-64e4-45cb-8fde-565f0d59ddd2",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "d825d455-247e-4f93-ad42-44561d682c18",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  }
                ]
              },
              {
                "id": "888aac34-03db-4777-9e71-0c3308e4a6db",
                "name": "Blood Chemistry",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "3c1393f7-2edd-4226-b57c-f79cccf133eb",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "3e4a8333-f1c5-417b-bd07-9b7692f02f11",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "a2d32b1c-91ad-45ad-9bc3-84f85a72c278",
                "name": "Blood Chemistry Testing",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "470a8f3a-eb30-426b-8324-bd59b4b0f5a3",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "c83ff4ba-aca0-44f8-94a2-c24a559491c2",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "3d661661-79e6-41f0-9234-21403843dc90",
                "name": "CT/MRI Scans of Chest, Abdomen, Pelvis, any clinically indicated sites of disease, and of bone lesions; Clinical evaluation of superficial disease",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "61e3a78e-54bd-468a-9d70-c0a4cf797ab2",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "3c5adbc3-f5a9-4a00-b8c7-2007ad08f3ca",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "f4aacffa-926e-4436-aba8-aca5705328e8",
                "name": "Computed Tomography Scan",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "371aacf2-b179-4b7a-bcb2-4e7babc9a516",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "9abb765d-7dd9-4425-a911-5357826f0a50",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "0dd044ea-d1fb-48e9-ba2a-d85937779341",
                "name": "ECOG Performance Status",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "c21dc4da-f960-4c7a-98ed-9927b23b29fb",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa,procedures"
                  },
                  {
                    "id": "4c2c0dc2-331b-43f4-ac29-62d01c207058",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "87e415cf-5b39-4ac4-bbe6-67994523e736",
                "name": "EuroQol-5D (EQ-5D)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "2be0e7fc-e0d2-4470-a563-60effc3fee61",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "d38d471c-ade8-43b3-9e9b-5e7b95c6d322",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  }
                ]
              },
              {
                "id": "41614ee3-44e1-419e-b48a-194fc9554732",
                "name": "European Organisation for Research and Treatment of Cancer Breast Cancer Module (EORTC-QLQ-BR23)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "3e39349d-8fbe-446b-9715-cb4d74a60b5c",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "302ef402-5427-4986-b854-1eeeaa08002a",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  }
                ]
              },
              {
                "id": "c4c108ae-8e2d-4f92-8fda-8a236dc55f1e",
                "name": "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "ce3b0e36-a4ab-4131-9eb7-b1609752074b",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "d013a593-9b8b-4f23-a900-467d0ac27020",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "assessment"
                  }
                ]
              },
              {
                "id": "4f53f4c8-0aa3-41b6-9a07-ffa5a692770f",
                "name": "For pre-/peri-menopausal patients only: Goserelin (both treatment arms, if applicable)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "fd0c2e79-0492-4742-bed8-9c29c53b76a9",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "cfe1b18d-61d7-4649-8fb8-ad12562c2310",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  }
                ]
              },
              {
                "id": "260a0149-2fd5-48dc-b384-f778f51a3371",
                "name": "Fulvestrant (both treatment arms)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "0071321d-7800-4d7a-9cf9-6d32a40e7fa9",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "1e9f81a9-4f8f-4af5-9e2c-f8f06e5a5d41",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  }
                ]
              },
              {
                "id": "a55b130b-1d36-49d2-8d76-8dd5c3502131",
                "name": "Fulvestrant Injection",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "9eb856b0-f872-413f-a852-cd68c8f7f9fe",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "d3efa30b-38b0-4311-bf51-e1920a36d058",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "1d685aa9-43e2-48b2-8331-95d77262c2ea",
                "name": "General Assessments",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "29f3b42c-e25a-462e-bded-e9c2f6e022ba",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "4a6fdd2c-15b5-4e55-8b04-31a49b9eba7b",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  }
                ]
              },
              {
                "id": "a49fde53-9ccc-49a4-841c-cdd00c72bfe4",
                "name": "Hematology",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "f54c391b-a11e-4a45-be3f-6c4c4d6790af",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "59106a1e-c86c-415f-a9ff-d0eebc962823",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "lab"
                  }
                ]
              },
              {
                "id": "42741322-671f-4b47-9cca-c43f515d9579",
                "name": "Hematology Testing",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "c1460ea8-bed6-48bc-a1ea-744db707070d",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "759e78e0-0ab8-4edb-ac0c-d4761e42e6be",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "51fbc0e7-58be-4e99-b006-b1f5232dd565",
                "name": "Hemoglobin A1c Test",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "9e5653a3-01fb-430e-a788-b593490e08cd",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "7018371e-307e-42b4-8fe3-a16bafda0244",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "1c8ab8e3-9bf1-4a32-94df-c9a08d35b4b9",
                "name": "Informed Consent",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "44b3b188-301c-4084-9d53-49ed070f9234",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "c91da11d-5f12-4b08-b216-1b28d7b539c5",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "documentation"
                  }
                ]
              },
              {
                "id": "de27fb12-cf48-4331-bca3-68efcafc7db9",
                "name": "Laboratory Studies",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "15825f77-9529-4963-ac5c-bc227ee91384",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "6ae804d1-108e-491a-93b7-41cb886ee6b0",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  }
                ]
              },
              {
                "id": "c537abf4-9731-4bc9-a7ad-be40108df405",
                "name": "Magnetic Resonance Imaging",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "15da558a-4b42-49e8-925c-929f97000a39",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "2d10f40e-fa5b-4862-946a-773fd3c84b65",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "01b7bf28-c38b-49a6-bc3b-4ec225bcdcfa",
                "name": "Medical/Oncological History",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "08b33bc8-5f73-4edb-8956-2cdffa220edb",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f6361963-c01d-432c-813f-6bfd4df30911",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  }
                ]
              },
              {
                "id": "1d7f9e83-9c37-41d7-9cb2-7670bc6aada6",
                "name": "Ophthalmic Examination",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "1267038a-3edb-458b-98c9-3cf9fe8153b7",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa,procedures"
                  },
                  {
                    "id": "a4a65e66-2935-4ef4-8a69-12eef185357a",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "c30a45e8-7009-4d29-b200-0104042e8694",
                "name": "Palbociclib or placebo (Arm A only)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "a6045ed6-79e6-4d85-b09b-44fa05610fbe",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "58c1696d-d836-4f46-bb6e-9c968c4d88d2",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  }
                ]
              },
              {
                "id": "c4c35261-5d15-4d4f-a19c-27fe998c6f2c",
                "name": "Pharmacokinetic Sampling",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "34f03337-6ffe-42f1-bc2a-c1ec188ec98e",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "df3c89ac-e70f-4a30-9223-a65f14166f6b",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "d15c94e8-2b2b-4f84-825b-ddb238424898",
                "name": "Pharmacokinetics (PK)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "65ce59ec-bb45-4549-a649-41427a62394c",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "6b9be3aa-ea2d-4700-944d-f470b835198a",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  }
                ]
              },
              {
                "id": "d7a92cc7-9744-4b99-98a2-762b15a664a4",
                "name": "Physical Examination",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "7133f631-aeac-40be-9c0d-7ad7bad39eb8",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "88be0d48-22a3-40d1-85cd-8b0c122b2584",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "ad6734e2-69b7-421e-9efb-6e475eff2803",
                "name": "Physical Examination/Vital Signs",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "dc6e4d59-26dc-48b3-817e-278c931a5969",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f7bae949-5445-4892-8268-5a616ad8563e",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "bb3e1c27-db73-4aba-a5bb-089151998e24",
                "name": "Pregnancy test, serum estradiol and FSH (if applicable)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "3f020ea7-6877-4bb2-9e0d-6930ceb9b059",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "22c4d237-4b60-40ae-9680-27049d61fb1d",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  }
                ]
              },
              {
                "id": "7709af2f-2f2a-4491-93c9-f5c3e030e06e",
                "name": "Radionuclide Bone Scan",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "40c34cc2-0a1f-4832-a453-6eb15709346b",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "c1f96208-330a-4eaa-b920-a4b2167a949e",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "2702a55f-09cc-4d89-a596-59636826c9ab",
                "name": "Radionuclide Bone Scan, Whole Body",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "4cf97693-8873-42f7-9786-6c8aef5afb5d",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "7fa53da5-46c0-414e-9709-d0b4bbf4a1eb",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  }
                ]
              },
              {
                "id": "d752206b-47f8-4faf-9342-08f04d2ab1c1",
                "name": "Randomization",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "1bfb6908-a49f-48b5-90b3-04f55106dd85",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "8b30a238-9e01-43bf-9144-7dc8eb82f83d",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "documentation"
                  }
                ]
              },
              {
                "id": "c81eb761-176f-464b-b848-d9378535eac4",
                "name": "Study Treatment",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "2fe15f67-49c6-40db-a4fc-890997036884",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "00d089cc-945f-4ae2-b2df-5dc045a12683",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  }
                ]
              },
              {
                "id": "0debd94f-dadf-4c78-b22e-4a221dd7a5b3",
                "name": "Survival Follow-up",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "a148bade-a18a-4b90-babf-260cb0a47f49",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa,procedures"
                  },
                  {
                    "id": "b862a58b-ab85-4e35-b15f-220ee84e656c",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "d636eb62-d567-475e-9caf-8d37147975cf",
                "name": "Tumor Assessment",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "588a4c84-2256-4e94-9aab-0cb087ad6b94",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "82aa0f8c-9216-4ea4-a963-9ea4893ae4b4",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "c3289b8a-b69b-4404-8268-88a5a85860ee",
                "name": "Venipuncture",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "c5e3e15b-26ae-4683-a2ca-d2dfe7459d49",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "bb0585d9-e570-4229-8f23-586e341f93bf",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              },
              {
                "id": "a84756b7-43b2-40df-a6c7-738699732ded",
                "name": "Vital Signs Assessment",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "3c8a5396-1186-4d9c-a052-bcf9f5edb8de",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "d24ab2e6-2e24-41da-a236-728bc518493d",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  }
                ]
              }
            ],
            "epochs": [
              {
                "id": "943cc10c-d7e0-4c6f-b68e-d48bbe63e0e0",
                "name": "Screening",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "1ffe405f-6324-4e84-80fb-453d9abdb39c",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "5dce3a51-ea29-470c-8666-09f6efdc73f5",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "876c51cc-eb4c-46f5-81bd-c158b8353695",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "a0368ab7-e944-4c73-9a9a-cbfccb80e9e7",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "1"
                  }
                ]
              },
              {
                "id": "799e1de1-23a0-4655-9aad-856b08d0e21f",
                "name": "Active Treatment Phasea - One Cycle = 28 days",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "51046992-329a-4dae-b0d5-9d89b12a2446",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "263cbf6b-8fb4-4c2d-86f6-2d23f8ab7edb",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "6369a354-a08f-4e7b-875e-bd2e2afc0201",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "sub"
                  }
                ]
              },
              {
                "id": "5a5ea0d9-c3fd-43b4-9958-9f01b57e2a56",
                "name": "End of Treatment/Withdrawalc",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "1ea007f8-c715-4dcc-bd28-a1ae464db50c",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "bbce65f0-c141-4f2a-b882-27f5b9493e42",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "08f3c5bd-2ec1-4ec6-b730-43fb6d84810c",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "sub"
                  }
                ]
              },
              {
                "id": "41864c37-b04e-42f6-a269-8894768c6064",
                "name": "Post-Treatment Follow-Upd",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "6832e817-9bb0-403b-b7d4-a1bd179227f6",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "6727dc2f-2071-4d9c-b8a1-16f03a11b6a9",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a51e11e0-47e0-438c-8f02-ab4426f8c0d3",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "sub"
                  }
                ]
              },
              {
                "id": "9c78e606-e705-4707-85b0-d813ff2000ad",
                "name": "Period 1",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "cc5b9744-2e7e-4d06-9425-1a42dea96106",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "1eec851d-f612-4c6b-afa1-b759927a949c",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "8dff8e1f-ee8c-455f-ad8b-98b01fa70185",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "sub"
                  }
                ]
              },
              {
                "id": "9d57ef6c-9237-4502-87df-7c4ab1adfcdb",
                "name": "Period 2",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "f0b23c00-4b74-41c4-8bc2-950d479a1e32",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "3ae27b62-bb75-494c-be49-88a36d7f0853",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a605c922-5296-4bd9-b112-555665e42a3a",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "sub"
                  }
                ]
              },
              {
                "id": "46d4b020-6025-407d-a4ff-95d0ec0bc62b",
                "name": "End of Study",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "4c7a1286-8041-4656-84ef-0d78f02ae5c1",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "f0093008-838b-4d84-90d6-64e3531374c4",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "066b9f79-457a-4289-a771-6ade94acf7ae",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "sub"
                  }
                ]
              },
              {
                "id": "9e1cab77-6497-41c1-854b-9121a78c25dd",
                "name": "Early Termination",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "9a7fa31f-4545-4001-87fe-b20a99a682ba",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "8411802f-5d18-4679-957d-efb186ca2c37",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "b31b4a76-a3e2-4d0e-a192-8c3ec4e784fa",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "bec56a54-466e-4cb1-94ab-f4c1785d9ad6",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "2"
                  }
                ]
              }
            ],
            "notes": [
              {
                "id": "a575c02b-873b-4c9b-8b8c-64b80aa209d0",
                "text": "a. Active Treatment Phase: Assessments should be performed prior to dosing on the visit day unless otherwise indicated. Acceptable time windows for performing each assessment are described in the column headers. No time window is to be considered for treatment schedule of palbociclib/placebo. One cycle consists of 28 days. A cycle could be longer than 28 days if persistent toxicity delays initiation of the subsequent cycle. Day 1 of any cycle visit should coincide with the day the palbociclib/placebo treatment begins. If there are delays due to toxicity, then the start of the next cycle visit will be delayed until the patient has recovered and can begin study treatment again. Fulvestrant injection will be given every 28 days (+/- 7 days) with the exception of Cycle 1 during which it will be administered on Days 1 and 15 (±2 days allowed according to the protocol visit time windows). Goserelin will be administered every 28 days (+/- number of days allowed according to the protocol visit time windows). The active treatment phase is ongoing as long as the patient is receiving both study drugs (ie, palbociclib/placebo and fulvestrant) or fulvestrant alone.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "c03a2d5a-f242-4acf-b543-8c4a05fb1efe",
                "text": "b. Cycle 1/Day 1: Blood chemistry, hematology, and physical examination not required if acceptable screening assessment is performed within 7 days prior to randomization.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "649b8e97-11d6-4360-b727-a05dad7e6470",
                "text": "c. End of Treatment/Withdrawal: Visit to be performed as soon as possible but no later than 4 weeks from the last dose of investigational products and prior to initiation of any new anticancer therapy. Obtain assessments if not completed during the previous 4 weeks on study.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "05fbb636-f471-414c-8147-b766b4b9068f",
                "text": "d. Post Treatment Follow-Up: Patients who discontinue study treatment should be contacted 28 calendar days (±7 days) after discontinuation of study treatment (palbociclib/placebo or fulvestrant) to assess if there have been any new adverse events and/or any change to any previously reported adverse events. This follow-up should occur 28 calendar days (±7 days) regardless of any new anti-cancer therapy that may have started. Telephone contact is acceptable. Follow-up visits to assess survival status will be conducted every 3 months going forward after approval of Amendment 3. See table footnote s (Survival Follow-up) below.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "c749ede2-5920-4670-ab26-46df57be7d4d",
                "text": "e. Informed Consent: Informed consent must be obtained prior to any protocol required assessments being performed (with the exception of certain imaging assessments if meeting the criteria defined in the Screening Section).",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "c64564aa-3365-42ad-af76-8cda9cb5f01c",
                "text": "f. Medical/Oncological History: To include information on prior anticancer treatments.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "e33c5cca-8499-406b-803c-235ff3fb60a5",
                "text": "g. Baseline Signs/Symptoms: Baseline tumor related signs and symptoms will be recorded at the Cycle 1 Day 1 visit prior to initiating treatment and then reported as adverse events during the last if they worsen in severity or increase in frequency.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "7b885708-568d-4789-aa48-c94fd110dc5e",
                "text": "h. Physical Examination/Vital Signs: A full physical examination including an examination of all major body systems and breasts, height (at screening only), weight, blood pressure and pulse rate, which may be performed by a physician, registered nurse or other qualified health care provider. Physical examinations will be carried out at Screening, Day 1 of every cycle and the End of Treatment/Withdrawal visit.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "931f085b-205b-4db0-87fd-57be078f69b7",
                "text": "i. Ophthalmic Examinations: Upon approval of Amendment 1, newly enrolled lens grading evaluable patients will undergo an ophthalmic examination by an ophthalmologist at screening, during study treatment on Cycle 4 Day 1, on Cycle 7 Day 1, on Cycle 13 Day 1 (ie, after 3, 6 and 12 months), every 12 months thereafter (ie, Days 1 of Cycles 25, 37, etc.) and at the End of Treatment/Withdrawal visit. Additional ophthalmic examinations may be performed as clinically indicated. It is expected that a minimum of 100 evaluable patients will participate in these examinations. Sites will be informed once these examinations are no longer required for patients newly enrolled in this study. Refer to the Ocular Safety Assessments Section for further details. Upon approval of Amendment 3, ophthalmic tests will continue to be collected.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "54f05768-6899-48da-ba1d-36696a5f007b",
                "text": "j. Laboratory tests: Hematology includes hemoglobin, WBC, absolute neutrophil count, platelet count. Hematology tests must meet retreatment criteria prior to administering palbociclib. Blood chemistry includes AST/ALT, alkaline phosphatase, sodium, potassium, magnesium, total calcium, total bilirubin, blood urea nitrogen (BUN) (or urea), serum creatinine, and albumin. Additional hematology/chemistries panels may be performed as clinically indicated. Upon approval of Amendment 3, hemoglobin A1c will be measured in all patients every 3 cycles (Day 1) going forward (C7D1, C10D1, C13D1, etc) and at the End of Treatment/Withdrawal visit. Pregnancy test (serum) at screening only for women of childbearing potential. Test may be repeated as per request of IRB/IECs or if required by local regulations. Serum estradiol and Follicle stimulating hormone (FSH) levels are analysed at screening to confirm postmenopausal status of women <60 years old and who have been amenorrheic for at least 12 consecutive months. Upon approval of Amendment 3, blood chemistry will be performed every 3 cycles (Day 1) going forward (C7D1, C10D1, C13D1, etc) and at the End of Treatment/Withdrawal visit. Hemoglobin A1c will be tested at the time of blood chemistry. If an adverse event occurs that mandates blood chemistry to be performed for hepatic function abnormality, the additional laboratory data will be recorded in the CRF.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "cbef49e8-27f8-4e65-8ee7-32259f782800",
                "text": "k. CT/MRI Scans of Chest, Abdomen, Pelvis: Upon approval of Amendment 3, tumor assessments will be performed as per local practice. Refer to the tumor assessment requirement flowchart.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "e05c6372-8f71-4508-a82f-adcc41f7b2f4",
                "text": "l. Radionuclide Bone Scan, Whole Body: Upon approval of Amendment 3, tumor assessments will be performed as per local practice. Refer to the tumor assessment requirement flowchart.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "c0fee3c9-bdaf-43b8-b003-5d00d09fd212",
                "text": "m. Adverse Events (AEs): Serious Adverse events (SAEs) must be reported from the time the patient provides informed consent through and including 28 calendar days after the last administration of the study drug. SAEs occurring after the active reporting period has ended should be reported if the investigator becomes aware of them; at a minimum, all SAEs that the investigator believes have at least a reasonable possibility of being related to study drug are to be reported to the Sponsor. All AEs (serious and non serious) should be recorded on the CRF from the first dose of study treatment through last patient visit. It is expected that telephone contact with the patient will be made in order to assess SAEs and AEs 28 calendar days (+/- 7 days) after the last administration of the study drug.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "15a2b236-b763-4567-b271-b4632f8cb4e4",
                "text": "n. Pharmacokinetics (PK): In approximately the first 40 patients randomized in the study, plasma PK samples will be drawn pre-dose on Day 1 and Day 15 of Cycle 1 and 2, and Day 1 of Cycle 3 for DDI assessment for palbociclib and fulvestrant (and goserelin if applicable). In all other patients, plasma concentrations will be drawn on Day 15 of Cycle 1 and Cycle 2 for palbociclib only. Additional PK blood samples may be collected from patients experiencing unexpected or serious adverse events, or adverse events that lead to discontinuation.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "874644c6-1fbb-4423-aeaf-9aa6e4ae08d1",
                "text": "r. Patient Reported Outcomes Assessments: All self-assessment questionnaires must be completed by the patients while in the clinic and cannot be taken home. Interviewer administration in clinic may be used under special circumstances.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "9b693b66-4899-48f4-b11f-2511848aead8",
                "text": "s. Survival Follow-Up: Upon approval of Amendment 3, for patients who discontinue study treatment, survival data will be collected every 3 months going forward. Telephone contact is acceptable. During follow-up visits the following data will be recorded in the CRF: 1) start, stop and type of new anticancer therapy; 2) tumor response of new anticancer therapy; 3) date of progression of the disease during or after the new antitumor agent; 4) survival status.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "f841bfd8-24cb-4630-91a4-51e447e4693e",
                "text": "t. Fulvestrant: To be administered on-site according to the local Summary of Product Characteristics for fulvestrant (Faslodex®). Fulvestrant injection will be given every 28 days (+/- 7 days) with the exception of Cycle 1 during which it will be administered on Days 1 and 15 (±2 days allowed according to the protocol visit time windows).",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "a8f7a36e-a627-4d8a-8537-5c6710834c68",
                "text": "u. Palbociclib or Placebo: Patients will be required to return all bottles of palbociclib/placebo as well as the completed patient diary on Day 1 of each cycle for drug accountability.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "29066f37-b41c-419f-ab78-b5d42e4fd038",
                "text": "v. Goserelin (if applicable): Goserelin will be administered every 28 days (+/- number of days allowed according to the protocol visit time windows). Treatment with goserelin (Zoladex® or generic) as per local practice for all women who are pre- or peri-menopausal at study entry. Patients must have commenced treatment with goserelin or an alternative luteinizing hormone-releasing hormone (LHRH) agonist at least 4 weeks prior to randomization. If patients have not received goserelin as their LHRH agonist prior to study entry, they must switch to goserelin for the duration of the trial. It is recommended to administer goserelin (given every 28 days) on-site when monthly fulvestrant is given. If goserelin is administered at home by the patient, a patient diary will be completed.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "a61b86f2-6639-4a03-961f-cee239b4c99b",
                "text": "\nProtocol Summary-Background and \nRationale/Section",
                "instanceType": "Note"
              },
              {
                "id": "895333ae-e98f-448a-9fb9-cbd51f7d21e4",
                "text": "\nProtocol Summary-Schedule of Activities: \nClarified that ophthalmology tests will continue \nto be collected",
                "instanceType": "Note"
              },
              {
                "id": "ba900881-5e52-42e9-9139-f7ea4856faf5",
                "text": "\nProtocol Summary-Tumor Assessment \nRequirements Flow Chart/Section",
                "instanceType": "Note"
              },
              {
                "id": "e1872519-3e39-438a-8d7c-5632778a27fe",
                "text": "Human Pharmacokinetic Data: \nUpdated section to add data findings to support:",
                "instanceType": "Note"
              }
            ],
            "model": {
              "id": "aec897f0-aecb-446c-ae6d-57f096145467",
              "code": "C49649",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Crossover Study",
              "instanceType": "Code"
            },
            "indications": [
              {
                "id": "da0e2195-5c40-4262-99e2-bb949a92f575",
                "name": "Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer",
                "isRareDisease": false,
                "instanceType": "Indication",
                "description": "Women with hormone receptor-positive, HER2-negative metastatic breast cancer whose disease progressed after prior endocrine therapy"
              }
            ],
            "procedures": [
              {
                "id": "c3289b8a-b69b-4404-8268-88a5a85860ee",
                "name": "Venipuncture",
                "procedureType": "Biospecimen Collection",
                "code": {
                  "id": "5758970d-20a7-47ba-a6c1-635ce6202c3c",
                  "code": "36415",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collection of venous blood by venipuncture",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Blood Draw",
                "description": "Collection of blood for laboratory studies including hematology, blood chemistry, pregnancy tests, hormone levels, and pharmacokinetics."
              },
              {
                "id": "be1f2705-2877-4e02-bae8-89b015998c44",
                "name": "12-Lead Electrocardiogram",
                "procedureType": "Diagnostic Procedure",
                "code": {
                  "id": "6d174426-0be7-4b90-b84e-ae478d8f0c5e",
                  "code": "93000",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "12-Lead ECG",
                "description": "A 12-lead ECG performed in triplicate to assess cardiac function."
              },
              {
                "id": "f4aacffa-926e-4436-aba8-aca5705328e8",
                "name": "Computed Tomography Scan",
                "procedureType": "Imaging Technique",
                "code": {
                  "id": "060a8c37-6012-4779-b495-5ffc02fed75d",
                  "code": "74177",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Computed tomography, abdomen and pelvis; without contrast material",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "CT Scan",
                "description": "CT scans of the chest, abdomen, pelvis, and any other clinically indicated sites of disease for tumor assessment."
              },
              {
                "id": "c537abf4-9731-4bc9-a7ad-be40108df405",
                "name": "Magnetic Resonance Imaging",
                "procedureType": "Imaging Technique",
                "code": {
                  "id": "9dbd5413-e30a-4882-93ce-7acd8d74187a",
                  "code": "74183",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by contrast material(s) and further sequences",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "MRI",
                "description": "MRI scans of the chest, abdomen, pelvis, and any other clinically indicated sites of disease for tumor assessment."
              },
              {
                "id": "51fbc0e7-58be-4e99-b006-b1f5232dd565",
                "name": "Hemoglobin A1c Test",
                "procedureType": "Diagnostic Procedure",
                "code": {
                  "id": "04d7adc8-04c0-44d5-92da-0fea31d1a8eb",
                  "code": "83036",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Hemoglobin; glycosylated (A1C)",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "HbA1c Test",
                "description": "Prospective monitoring of hemoglobin A1c to characterize whether or not palbociclib affects glucose metabolism."
              },
              {
                "id": "d636eb62-d567-475e-9caf-8d37147975cf",
                "name": "Tumor Assessment",
                "procedureType": "Assessment",
                "code": {
                  "id": "78b899b5-2c8d-4e07-b7f4-78b6446f8873",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Tumor Assessment",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Tumor Assessment",
                "description": "Evaluation of tumor response using imaging studies (CT, MRI, Bone Scan) and clinical evaluation, initially guided by RECIST version 1.1."
              },
              {
                "id": "a55b130b-1d36-49d2-8d76-8dd5c3502131",
                "name": "Fulvestrant Injection",
                "procedureType": "Therapeutic Procedure",
                "code": {
                  "id": "3b5d4ae7-8890-451a-93a2-b7a3f254f365",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Fulvestrant Injection",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Fulvestrant Injection",
                "description": "Administration of fulvestrant via injection."
              }
            ],
            "extensionAttributes": [
              {
                "id": "6a289dbc-91e6-47ae-a7d8-4c4a92655e29",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-promotionIssues",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"severity\": \"warning\", \"category\": \"timing_reference_remapped\", \"message\": \"Timing 'Screening Window' reference remapped: 37f5eff3-fe90-4409-86b6-23aaa842ea87 → 3beb9bb4-d09b-4d2d-897e-cebd5c0b23aa\", \"affectedPath\": \"$.timings[?(@.id=='timing_1')]\"}, {\"severity\": \"warning\", \"category\": \"timing_reference_remapped\", \"message\": \"Timing 'Cycle 1 Day 1 Visit Window' reference remapped: e2a6e2ec-127f-4d04-b6ae-b36d5343cfd3 → d536aef6-1a3b-45bd-9b23-d57f0a1fd227\", \"affectedPath\": \"$.timings[?(@.id=='timing_2')]\"}, {\"severity\": \"warning\", \"category\": \"timing_reference_remapped\", \"message\": \"Timing 'Cycle 1 Day 15 Visit Window' reference remapped: 5d76bc67-4f88-4bf1-9994-b65bd535528e → d536aef6-1a3b-45bd-9b23-d57f0a1fd227\", \"affectedPath\": \"$.timings[?(@.id=='timing_3')]\"}, {\"severity\": \"warning\", \"category\": \"timing_reference_remapped\", \"message\": \"Timing 'Cycles >=3 Day 1 Visit Window' reference remapped: d72bd7f4-67d2-4a68-9de0-6f3fa0397732 → d536aef6-1a3b-45bd-9b23-d57f0a1fd227\", \"affectedPath\": \"$.timings[?(@.id=='timing_4')]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: 5e290bad-951d-45f8-b59e-246fd8910b42\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: 512b1d10-5376-4866-abcb-26c27c880cf2\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: a5d03641-a6aa-4fc1-a4c5-bebeb2c6f5fc\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: 909e2f0c-c8b9-456e-ba54-03c2f690ef2b\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: b8d70b26-df8a-4dd9-ad63-c46eb03ef4de\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: 8e61f977-0187-4f05-b9e8-f848a04c8018\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: eec8aff2-3c2d-4a44-aef2-f47675a38578\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"warning\", \"category\": \"timing_reference_remapped\", \"message\": \"Timing 'Cycle 1 Day 1 Assessment Window' reference remapped: e40fd9c1-52e4-4298-89ba-1f282a6d1499 → d536aef6-1a3b-45bd-9b23-d57f0a1fd227\", \"affectedPath\": \"$.timings[?(@.id=='timing_12')]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: d285afa1-b8b9-4ff5-ac13-a620c8b54f61\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: c990d6a7-ee14-430a-9189-f3596f25d1af\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: d9bcbf02-70c0-48c9-b311-2b64cbabdbd5\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}]"
              },
              {
                "id": "7a1bd6bb-20df-4e78-a765-3c78f6133a07",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-timeAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"anchor_1\", \"definition\": \"First administration of investigational product\", \"anchorType\": \"FirstDose\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"first dose of study treatment\"}, {\"id\": \"anchor_3\", \"definition\": \"Day 1 of Cycle 1\", \"anchorType\": \"CycleStart\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"Cycle 1 Day 1\"}, {\"id\": \"anchor_2\", \"definition\": \"Informed consent obtained\", \"anchorType\": \"InformedConsent\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"Informed Consent\"}, {\"id\": \"anchor_4\", \"definition\": \"procedure\", \"anchorType\": \"Custom\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"procedure\"}]"
              },
              {
                "id": "3b1b31fd-00f5-4448-87d6-a897059ba7ea",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-repetitions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"rep_daily_1\", \"type\": \"Daily\", \"startOffset\": \"P1D\", \"endOffset\": \"P21D\", \"interval\": \"P1D\", \"sourceText\": \"once daily\"}, {\"id\": \"rep_daily_3\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"od\"}, {\"id\": \"rep_daily_34\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"OD\"}, {\"id\": \"rep_daily_41\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"QD\"}, {\"id\": \"rep_daily_71\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"daily oral administration\"}, {\"id\": \"rep_interval_1\", \"type\": \"Interval\", \"sourceText\": \"tid\"}, {\"id\": \"rep_cycle_1\", \"type\": \"Cycle\", \"cycleLength\": \"P28D\", \"sourceText\": \"28-day cycle\"}, {\"id\": \"rep_cycle_3\", \"type\": \"Cycle\", \"sourceText\": \"Cycle 1 Day 1\"}, {\"id\": \"rep_cycle_4\", \"type\": \"Cycle\", \"sourceText\": \"Cycle 4 Day 1\"}, {\"id\": \"rep_cycle_5\", \"type\": \"Cycle\", \"sourceText\": \"Cycle 7 Day 1\"}, {\"id\": \"rep_cycle_6\", \"type\": \"Cycle\", \"sourceText\": \"Cycle 13 Day 1\"}, {\"id\": \"rep_cycle_7\", \"type\": \"Cycle\", \"sourceText\": \"C7D1\"}, {\"id\": \"rep_cycle_8\", \"type\": \"Cycle\", \"sourceText\": \"C10D1\"}, {\"id\": \"rep_cycle_9\", \"type\": \"Cycle\", \"sourceText\": \"C13D1\"}, {\"id\": \"rep_window_1\", \"type\": \"Continuous\", \"startOffset\": \"P1D\", \"endOffset\": \"P21D\", \"sourceText\": \"Days 1 to 21\"}, {\"id\": \"rep_window_2\", \"type\": \"Continuous\", \"startOffset\": \"P1D\", \"endOffset\": \"P21D\", \"sourceText\": \"Days 1- 21\"}, {\"id\": \"rep_window_3\", \"type\": \"Continuous\", \"sourceText\": \"treatment period\"}, {\"id\": \"rep_window_4\", \"type\": \"Continuous\", \"sourceText\": \"treatment phase\"}, {\"id\": \"rep_window_5\", \"type\": \"Continuous\", \"sourceText\": \"Treatment Phase\"}, {\"id\": \"rep_window_10\", \"type\": \"Continuous\", \"sourceText\": \"follow-up phase\"}, {\"id\": \"rep_window_11\", \"type\": \"Continuous\", \"sourceText\": \"28 days after\"}, {\"id\": \"rep_window_12\", \"type\": \"Continuous\", \"sourceText\": \"1 hour before\"}, {\"id\": \"rep_window_13\", \"type\": \"Continuous\", \"sourceText\": \"2 hours after\"}, {\"id\": \"rep_window_16\", \"type\": \"Continuous\", \"sourceText\": \"10 hours before\"}, {\"id\": \"rep_window_18\", \"type\": \"Continuous\", \"sourceText\": \"6 days before\"}, {\"id\": \"rep_window_19\", \"type\": \"Continuous\", \"sourceText\": \"2 hours before\"}, {\"id\": \"rep_window_21\", \"type\": \"Continuous\", \"sourceText\": \"10 hours \\nbefore\"}, {\"id\": \"rep_window_25\", \"type\": \"Continuous\", \"sourceText\": \"7 days \\nafter\"}, {\"id\": \"rep_llm_1\", \"type\": \"Cycle\", \"startOffset\": \"P0D\", \"sourceText\": \"blood chemistry will be performed every 3 cycles (Day 1) after approval of Amendment 3\"}]"
              },
              {
                "id": "daca811e-6d9d-462d-8fec-ce627b3d81aa",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-crossoverDesign",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"crossover_1\", \"isCrossover\": true, \"numPeriods\": 2, \"numSequences\": 2, \"periods\": [\"Period 1\", \"Period 2\"], \"sequences\": [\"AB\", \"BA\"], \"washoutRequired\": false, \"sourceText\": \"Crossover\"}"
              },
              {
                "id": "01406f2e-c27e-4344-8f85-e9357773109e",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-traversalConstraints",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"traversal_crossover_1\", \"requiredSequence\": [\"epoch_1\", \"period_1\", \"period_2\", \"epoch_end_of_study\"], \"allowEarlyExit\": true, \"exitEpochIds\": [\"epoch_early_termination\"], \"mandatoryVisits\": [\"enc_1\", \"enc_2\", \"enc_5\"], \"sourceText\": \"Crossover\"}, {\"id\": \"traversal_1\", \"requiredSequence\": [\"epoch_1\", \"epoch_2\", \"epoch_3\", \"epoch_4\"], \"allowEarlyExit\": true, \"exitEpochIds\": [\"epoch_early_termination\"], \"mandatoryVisits\": [\"enc_1\", \"enc_2\", \"enc_2\", \"enc_5\"], \"sourceText\": \"[{'condition': 'If subject discontinues treatment due to adverse events', 'path': ['EARLY_TERMINATION_VISIT', '28_DAY_SAFETY_FOLLOW_UP']}, {'condition': 'If subject discontinues treatment for reasons other than disease progression', 'path': ['EARLY_TERMINATION_VISIT', 'SURVIVAL_FOLLOW_UP']}, {'condition': 'If subject discontinues treatment due to disease progression', 'path': ['EARLY_TERMINATION_VISIT', 'SURVIVAL_FOLLOW_UP']}, {'condition': 'If subject permanently discontinues palbociclib/placebo', 'path': ['FULVESTRANT_MONOTHERAPY', 'FOLLOW_UP']}]\"}]"
              },
              {
                "id": "5818651e-41bf-4965-94ad-196e1073b4e3",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-footnoteConditions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"fn_cond_1\", \"conditionType\": \"general\", \"text\": \"\\nProtocol Summary-Background and \\nRationale/Section\", \"footnoteId\": \"f.\", \"sourceText\": \"\\nProtocol Summary-Background and \\nRationale/Section\"}, {\"id\": \"fn_cond_2\", \"conditionType\": \"general\", \"text\": \"\\nProtocol Summary-Study Design/Schedule of \\nActivities/Section\", \"footnoteId\": \"d.\", \"sourceText\": \"\\nProtocol Summary-Study Design/Schedule of \\nActivities/Section\", \"appliesToActivityIds\": [\"grp_7\"]}, {\"id\": \"fn_cond_3\", \"conditionType\": \"general\", \"text\": \"The \\ninvestigators will stop sending the imaging\\nstudies to the central laboratory\", \"footnoteId\": \"a.\", \"structuredCondition\": \"procedure.stop(send_to_central_lab, imaging_studies)\", \"appliesToActivityIds\": [\"grp_2\"], \"sourceText\": \"The \\ninvestigators will stop sending the imaging\\nstudies to the central laboratory\"}, {\"id\": \"fn_cond_5\", \"conditionType\": \"general\", \"text\": \"\\nProtocol Summary-Schedule of Activities: \\nClarified that ophthalmology tests will continue \\nto be collected\", \"footnoteId\": \"y.\", \"sourceText\": \"\\nProtocol Summary-Schedule of Activities: \\nClarified that ophthalmology tests will continue \\nto be \"}, {\"id\": \"fn_cond_6\", \"conditionType\": \"general\", \"text\": \"\\nProtocol Summary-Tumor Assessment \\nRequirements Flow Chart/Section\", \"footnoteId\": \"b.\", \"sourceText\": \"\\nProtocol Summary-Tumor Assessment \\nRequirements Flow Chart/Section\"}, {\"id\": \"fn_cond_7\", \"conditionType\": \"general\", \"text\": \"\\nSchedule of Activities/Study design: Added \\nclarification to the schedule of administration of \\nfulvestrant and goserelin\", \"footnoteId\": \"m.\", \"sourceText\": \"\\nSchedule of Activities/Study design: Added \\nclarification to the schedule of administration of \\nfu\", \"appliesToActivityIds\": [\"grp_7\", \"act_20\", \"act_22\"]}, {\"id\": \"fn_cond_8\", \"conditionType\": \"general\", \"text\": \"Refer to STUDY PROCEDURES and \\nASSESSMENTS sections of the protocol for detailed information on each procedure and assessment required for compliance with the \\nprotocol\", \"footnoteId\": \"s.\", \"sourceText\": \"Refer to STUDY PROCEDURES and \\nASSESSMENTS sections of the protocol for detailed information on each\", \"appliesToActivityIds\": [\"grp_7\", \"grp_1\"]}, {\"id\": \"fn_cond_9\", \"conditionType\": \"general\", \"text\": \"Upon approval, \\nsome of the safety and efficacy assessments\\nwill be reduced due to:\", \"footnoteId\": \"3.\", \"sourceText\": \"Upon approval, \\nsome of the safety and efficacy assessments\\nwill be reduced due to:\", \"appliesToActivityIds\": [\"grp_1\"]}, {\"id\": \"fn_cond_10\", \"conditionType\": \"general\", \"text\": \"As a consequence, the \\nrequirement of conducting tumor assessment at \\nthe End of Treatment visit will not be \\nmandatory any longer\", \"footnoteId\": \"3.\", \"structuredCondition\": \"procedure.mandatory(tumor_assessment, false) WHERE timepoint == 'End of Treatment'\", \"appliesToActivityIds\": [\"grp_7\"], \"sourceText\": \"As a consequence, the \\nrequirement of conducting tumor assessment at \\nthe End of Treatment visit wil\"}, {\"id\": \"fn_cond_11\", \"conditionType\": \"general\", \"text\": \"It was also clarified that, if \\nan adverse event occurs that mandates blood \\nchemistry to be performed\", \"footnoteId\": \"3.\", \"sourceText\": \"It was also clarified that, if \\nan adverse event occurs that mandates blood \\nchemistry to be perform\", \"appliesToActivityIds\": [\"act_8\", \"act_13\"]}, {\"id\": \"fn_cond_12\", \"conditionType\": \"general\", \"text\": \"Human Pharmacokinetic Data: \\nUpdated section to add data findings to support:\", \"footnoteId\": \"2.\", \"sourceText\": \"Human Pharmacokinetic Data: \\nUpdated section to add data findings to support:\"}]"
              },
              {
                "id": "d944c475-6abb-4af9-86d9-0b4509cbab84",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-endpointAlgorithms",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"ep_1\", \"name\": \"Investigator-Assessed Progression-Free Survival (PFS)\", \"endpointType\": \"Primary\", \"inputs\": [\"randomization_date\", \"date_of_objective_progression\", \"date_of_death\"], \"timeWindow\": {\"reference\": \"randomization\", \"duration\": \"Until disease progression or death\"}, \"algorithm\": \"Time from randomization to the first documentation of objective disease progression or death from any cause, whichever occurs first. PFS = MIN(date_of_objective_progression, date_of_death) - randomization_date.\", \"successCriteria\": \"Demonstrate superiority of the palbociclib + fulvestrant arm over the fulvestrant alone arm in prolonging PFS.\", \"sourceText\": \"To demonstrate the superiority of palbociclib in combination with fulvestrant (with or without goserelin) over fulvestrant alone (with or without goserelin) in prolonging investigator-assessed PFS in \"}, {\"id\": \"ep_2\", \"name\": \"Safety Comparison\", \"endpointType\": \"Secondary\", \"inputs\": [\"adverse_events_data\", \"treatment_arm\"], \"timeWindow\": {\"reference\": \"start of treatment\", \"duration\": \"Throughout the active treatment period\"}, \"algorithm\": \"Comparison of the incidence, severity, and type of adverse events between the two treatment arms.\", \"successCriteria\": \"Characterize and compare the safety profile of the palbociclib combination arm versus the placebo combination arm.\", \"sourceText\": \"The safety between the two treatment arms will also be compared.\"}, {\"id\": \"ep_3\", \"name\": \"Patient Reported Outcomes (PRO) / Quality of Life (QoL)\", \"endpointType\": \"Secondary\", \"inputs\": [\"PRO_questionnaire_scores\", \"treatment_arm\", \"assessment_timepoint\"], \"timeWindow\": {\"reference\": \"start of treatment\", \"duration\": \"Throughout the active treatment period\"}, \"algorithm\": \"Comparison of global Quality of Life (QoL) scores and other health-related quality of life metrics between the two treatment arms over time.\", \"successCriteria\": \"Demonstrate a statistically significantly higher on-treatment global QoL in the palbociclib arm compared to the placebo arm, or maintenance of QoL.\", \"sourceText\": \"Patient Reported Outcomes (PRO) will be collected to evaluate health-related quality of life and health status.\"}, {\"id\": \"ep_4\", \"name\": \"Molecular Profiling for Sensitivity and Resistance\", \"endpointType\": \"Exploratory\", \"inputs\": [\"tumor_tissue_molecular_data\", \"clinical_outcome_data\"], \"timeWindow\": {\"reference\": \"baseline\", \"duration\": \"N/A (correlative analysis)\"}, \"algorithm\": \"Assess the relationship between the alteration of cell cycle pathway-related genes and proteins in tumor tissues and clinical outcomes (sensitivity and resistance) to palbociclib.\", \"successCriteria\": \"Identify potential biomarkers of response or resistance to palbociclib.\", \"sourceText\": \"The study will also include a molecular profiling component aimed at assessing the relationship between breast tumor sensitivity and resistance to palbociclib and the alteration of cell cycle pathway-\"}]"
              },
              {
                "id": "6304155e-da77-4460-9188-939e647e114d",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-derivedVariables",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"dv_1\", \"name\": \"QTcF change from baseline\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"QTcF\"], \"derivationRule\": \"Post-treatment QTcF value - Baseline QTcF value\", \"baselineDefinition\": \"Not specified\", \"baselineVisit\": \"Not specified\", \"analysisWindow\": \"Not specified\", \"imputationRule\": \"Not specified\", \"unit\": \"msec\"}, {\"id\": \"dv_2\", \"name\": \"Clinically significant decrease in best-corrected visual acuity\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"Best-corrected visual acuity\"], \"derivationRule\": \"A decrease of 3 or more lines from the Screening visit value. If screening acuity is better than 20/20, the decrease is calculated from 20/20. This is reported as an adverse event.\", \"baselineDefinition\": \"Value at the Screening visit. If acuity at screening is better than 20/20, baseline is considered 20/20 for calculation.\", \"baselineVisit\": \"Screening\", \"analysisWindow\": \"All subsequent study visits\", \"imputationRule\": \"Not specified\", \"unit\": \"lines\"}, {\"id\": \"dv_3\", \"name\": \"Clinically significant change in refraction power\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"Refraction power (spherical)\", \"Refraction power (cylindrical)\"], \"derivationRule\": \"A change (increase or decrease) of 1.25 diopters or more in spherical or cylindrical refraction power compared with the screening examination. This is reported as an adverse event.\", \"baselineDefinition\": \"Value at the screening examination.\", \"baselineVisit\": \"Screening\", \"analysisWindow\": \"Not specified\", \"imputationRule\": \"Not specified\", \"unit\": \"diopters\"}, {\"id\": \"dv_4\", \"name\": \"Adverse Event Trigger for Intraocular Pressure (IOP)\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"Intraocular pressure (IOP)\"], \"derivationRule\": \"An adverse event is reported if either of the following criteria are met: 1) IOP increase of greater than 10 mmHg above baseline, OR 2) any IOP that increases above 25 mm Hg.\", \"baselineDefinition\": \"Not specified for the 'increase from baseline' criterion.\", \"baselineVisit\": \"Not specified\", \"analysisWindow\": \"Not specified\", \"imputationRule\": \"Not specified\", \"unit\": \"mmHg\"}]"
              },
              {
                "id": "fad4c1e3-f266-41df-bd30-3405c3553101",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-stateMachine",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"sm_1\", \"initialState\": \"Screening\", \"terminalStates\": [\"Early Termination\", \"Completed\"], \"states\": [\"Screening\", \"Active Treatment Phasea - One Cycle = 28 days\", \"End of Treatment/Withdrawalc\", \"Post-Treatment Follow-Upd\", \"Early Termination\"], \"transitions\": [{\"fromState\": \"Screening\", \"toState\": \"Active Treatment Phasea - One Cycle = 28 days\", \"trigger\": \"Progress to Active Treatment Phasea - One Cycle = 28 days\"}, {\"fromState\": \"Active Treatment Phasea - One Cycle = 28 days\", \"toState\": \"End of Treatment/Withdrawalc\", \"trigger\": \"Progress to End of Treatment/Withdrawalc\"}, {\"fromState\": \"End of Treatment/Withdrawalc\", \"toState\": \"Post-Treatment Follow-Upd\", \"trigger\": \"Progress to Post-Treatment Follow-Upd\"}, {\"fromState\": \"Active Treatment Phasea - One Cycle = 28 days\", \"toState\": \"Early Termination\", \"trigger\": \"Subject exits to Early Termination\"}, {\"fromState\": \"End of Treatment/Withdrawalc\", \"toState\": \"Early Termination\", \"trigger\": \"Subject exits to Early Termination\"}, {\"fromState\": \"Post-Treatment Follow-Upd\", \"toState\": \"Early Termination\", \"trigger\": \"Subject exits to Early Termination\"}], \"epochIds\": {\"Screening\": \"epoch_1\", \"Active Treatment Phasea - One Cycle = 28 days\": \"epoch_2\", \"End of Treatment/Withdrawalc\": \"epoch_3\", \"Post-Treatment Follow-Upd\": \"epoch_4\", \"Early Termination\": \"EARLY_TERMINATION\"}}"
              },
              {
                "id": "7c6619da-77ac-440c-ac74-ca7d103755e9",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-dosingRegimens",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"dosing_1\", \"treatmentName\": \"RECIST version\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.1, \"unit\": \"g\"}], \"sourceText\": \" Section 6.6.1 (Active Treatment Phase Discontinuation) – Clarified that routine safety assessments must continue if patient continues study treatment despite progression of disease.  Appendix 4 (RE\"}]"
              },
              {
                "id": "d47bdbfe-8594-48ce-ac24-d3c825486107",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-visitWindows",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"visit_5\", \"visitName\": \"Screening\", \"targetDay\": -14, \"windowBefore\": 7, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 1, \"sourceText\": \"Screening Active Treatment Phasea - One Cycle = 28 days End of\"}, {\"id\": \"visit_8\", \"visitName\": \"Baseline\", \"targetDay\": 0, \"windowBefore\": 1, \"windowAfter\": 1, \"isRequired\": true, \"visitNumber\": 2, \"sourceText\": \"Baseline Signs/Symptomsg Xg Physical Examination/Vital Signsh\"}, {\"id\": \"visit_1\", \"visitName\": \"Early Termination\", \"targetDay\": 1, \"windowBefore\": 2, \"windowAfter\": 2, \"isRequired\": true, \"visitNumber\": 3, \"epoch\": \"Active Treatment\", \"sourceText\": \"some of the safety and efficacy assessments will be reduced due to: 1) completion of efficacy analyses including interim and final\"}, {\"id\": \"visit_3\", \"visitName\": \"End of Treatment\", \"targetDay\": 1, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 4, \"sourceText\": \"the End of Treatment visit will not be mandatory any longer. \"}, {\"id\": \"visit_4\", \"visitName\": \"Day 1\", \"targetDay\": 1, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 5, \"sourceText\": \"performed every 3 cycles (Day 1) after approval of Amendment 3. It was also clarified that, if an adverse event occurs that mandates blood\"}, {\"id\": \"visit_6\", \"visitName\": \"randomization\", \"targetDay\": 1, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 6, \"sourceText\": \"randomization unless specified otherwise Day 1b\"}, {\"id\": \"visit_10\", \"visitName\": \"end of study\", \"targetDay\": 1, \"windowBefore\": 3, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 7, \"sourceText\": \"evaluated at baseline, during and at the end of study treatment. By adding these examinations the sponsor is addressing a request by the Food and Drug Administration (FDA) for the palbociclib program.\"}, {\"id\": \"visit_9\", \"visitName\": \"Day 14\", \"targetDay\": 14, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 8, \"sourceText\": \"the pooled plasma samples on Day 14 of Cycle 1 indicated that the glucuronide conjugate of palbociclib and the lactam of palbociclib (PF-05089326) were the main metabolites present in plasma. Other me\"}, {\"id\": \"visit_7\", \"visitName\": \"Day 15\", \"targetDay\": 15, \"windowBefore\": 2, \"windowAfter\": 2, \"isRequired\": true, \"visitNumber\": 9, \"epoch\": \"Active Treatment\", \"sourceText\": \"Day 15 Day 1 Visit Window\"}, {\"id\": \"visit_11\", \"visitName\": \"Week 8\", \"targetDay\": 50, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 10, \"targetWeek\": 8, \"sourceText\": \"same assessment schedule (ie, Week 8 7 days from randomization) as for all other lesions. Areas that have received palliative radiotherapy cannot be used to assess response to study treatment.\"}, {\"id\": \"visit_2\", \"visitName\": \"Follow-up\", \"targetDay\": 365, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 11, \"sourceText\": \"under observation for a follow-up period of approximately 1 year and a half. \"}]"
              },
              {
                "id": "fd2af4b0-612f-44c6-b8a4-4d8b1ac99566",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-randomizationScheme",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"randomization_1\", \"ratio\": \"2:1\", \"method\": \"Stratified randomization\", \"centralRandomization\": true, \"stratificationFactors\": [{\"id\": \"strat_llm_1\", \"name\": \"Documented sensitivity to prior hormonal therapy\", \"categories\": [\"Yes\", \"No\"], \"isBlocking\": false}, {\"id\": \"strat_llm_2\", \"name\": \"Menopausal status at study entry\", \"categories\": [\"Pre-/peri-menopausal\", \"Post-menopausal\"], \"isBlocking\": false}, {\"id\": \"strat_llm_3\", \"name\": \"Presence of visceral metastases\", \"categories\": [\"Yes\", \"No\"], \"isBlocking\": false}], \"sourceText\": \"PD-0332991 (Palbociclib)\\nA5481023 (PALOMA-3)\\nFinal Protocol Amendment 3, 20 October2015\\nPFIZER CONFIDENTIAL\\nPage 10\\nIn the present study, adverse events seen with palbociclib and fulvestrant were cons\"}"
              }
            ],
            "administrations": [
              {
                "id": "24c145d3-e62f-4aa8-82a9-c7e4bfc010b6",
                "name": "RECIST version Administration",
                "instanceType": "Administration",
                "dose": "1.1 g",
                "doseFrequency": "QD",
                "route": {
                  "id": "bf27dd25-c820-4750-8ddc-8a10d93e1d3a",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "description": " Section 6.6.1 (Active Treatment Phase Discontinuation) – Clarified that routine safety assessments must continue if patient continues study treatment despite progression of disease.  Appendix 4 (RE"
              }
            ]
          }
        ],
        "titles": [
          {
            "id": "8635607d-890e-446e-b21e-9ef778e01d46",
            "text": "MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX) WITH OR WITHOUT PD-0332991 (PALBOCICLIB) GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY",
            "type": {
              "id": "8cf12c9b-622b-421f-b2c3-1066a39a719a",
              "code": "Official Study Title",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Official Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          },
          {
            "id": "a4341f1c-ef1e-44c1-bc72-1eb4d8ac985f",
            "text": "PALOMA-3",
            "type": {
              "id": "a6af6236-bd83-4859-8208-87decce5118d",
              "code": "Study Acronym",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Acronym",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          }
        ],
        "studyIdentifiers": [
          {
            "id": "c372c838-ffe6-426d-8dc8-c700d46cd9d9",
            "text": "69,324",
            "instanceType": "StudyIdentifier",
            "scopeId": "a19f1763-aa33-425a-aa17-3654c03014ed",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "248afcf4-f152-42b8-82e3-3e4fe44556df",
            "text": "2013-002580-26",
            "instanceType": "StudyIdentifier",
            "scopeId": "5b5435ee-526d-458e-8709-ab1dd43e48d9",
            "type": {
              "code": "C98714",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinical Trial Registry Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "530b4144-016d-49c3-aa5d-46481ab80de7",
            "text": "A5481023",
            "instanceType": "StudyIdentifier",
            "scopeId": "3f1ac349-a9eb-42e6-8bdf-10b980b6c006",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          }
        ],
        "organizations": [
          {
            "id": "3f1ac349-a9eb-42e6-8bdf-10b980b6c006",
            "name": "Pfizer",
            "type": {
              "id": "7d93b2fc-2acb-48b8-a92a-a73606f6cf1e",
              "code": "C54086",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Pharmaceutical Company",
              "instanceType": "Code"
            },
            "identifier": "Pfizer",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "5b5435ee-526d-458e-8709-ab1dd43e48d9",
            "name": "EudraCT",
            "type": {
              "id": "52baff76-429c-4ca9-9b75-0563b7c8741c",
              "code": "C19326",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Healthcare Facility",
              "instanceType": "Code"
            },
            "identifier": "EudraCT",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "a19f1763-aa33-425a-aa17-3654c03014ed",
            "name": "FDA",
            "type": {
              "id": "c639c78e-d4fe-4675-870b-535cfd3c586f",
              "code": "C25461",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Regulatory Agency",
              "instanceType": "Code"
            },
            "identifier": "FDA",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          }
        ],
        "studyPhase": {
          "id": "92e10a8d-84dc-4ff2-b412-06ec58a54fe0",
          "code": "Phase3",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Phase3",
          "instanceType": "Code"
        },
        "eligibilityCriterionItems": [
          {
            "id": "abd9a584-aa1c-4151-8999-4a5276c32c5c",
            "name": "Age and Menopausal Status",
            "text": "Women 18 years of age or older, who are either:\n\nPostmenopausal, as defined by at least one of the following criteria:\n\nAge 60 years;\n\nAge <60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and FSH level within the laboratory’s reference range for postmenopausal females;\n\nDocumented bilateral oophorectomy;\n\nMedically confirmed ovarian failure.\nOR\n\nPre/peri-menopausal, ie, not meeting the criteria for being postmenopausal.\n\nPre/perimeopausal women can be enrolled if amenable to be treated with the LHRH agonist goserelin. Patients must have commenced treatment with goserelin or an alternative LHRH agonist at least 4 weeks prior to randomization. But, if patients have received an alternative LHRH agonist prior to study entry, they must switch to goserelin for the duration of the trial.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "85892ace-8e94-4e70-a835-23f4e7dadf87",
            "name": "Diagnosis of Breast Cancer",
            "text": "Histologically or cytologically proven diagnosis of breast cancer with evidence of metastatic or locally advanced disease, not amenable to resection or radiation therapy with curative intent.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "b437645e-dd37-4628-9467-e86566280414",
            "name": "ER/PR Status",
            "text": "Documentation of ER-positive and/or PR-positive tumor (1% positive stained cells) based on most recent tumor biopsy (unless bone-only disease, see below) utilizing an assay consistent with local standards.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "88d685db-073b-4acd-b01d-aae8fd88ca57",
            "name": "HER2 Status",
            "text": "Documented HER2-negative tumor based on local testing on most recent tumor biopsy: HER2-negative tumor is determined as immunohistochemistry score 0/1+ or negative by in situ hybridization (FISH/CISH/SISH/DISH) defined as a HER2/CEP17 ratio <2 or for single probe assessment a HER2 copy number <4.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "081b7e2f-537c-4492-994c-dc5bce0bcf38",
            "name": "Prior Therapy Requirements",
            "text": "Patients must satisfy the following criteria for prior therapy: \n\nProgressed during treatment or within 12 months of completion of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre- or perimenopausal.\nOR\n\nProgressed while on or within 1 month after the end of prior aromatase inhibitor therapy for advanced/metastatic breast cancer if postmenopausal, or prior endocrine treatment for advanced/metastatic breast cancer if pre- or perimenopausal. \nOne previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "f0cdd571-36d7-477a-bfd1-ad9c28328dcc",
            "name": "Tumor Tissue Sample Provision",
            "text": "Except where prohibited by local regulations, all patients must agree to provide and have available a formalin-fixed paraffin embedded (FFPE) tissue biopsy sample taken at the time of presentation with recurrent or metastatic disease. A de novo biopsy is required if no archived tissue taken at the time of presentation with recurrent/metastatic disease is available. The sole exception is those patients with bone only disease for whom provision of previous archival tissue only is acceptable. Patients who had surgery within the last 3 years (but without neoadjuvant chemotherapy prior to surgery) and relapsed while receiving adjuvant therapy may provide a tumor specimen from that surgery.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "e0481db4-9a40-4d2d-a55c-9f51a5f0193d",
            "name": "Disease Measurability",
            "text": "Measurable disease as defined by RECIST version 1.1, or bone-only disease.  Patients with bone-only metastatic cancer must have a lytic or mixed lytic-blastic lesion that can be accurately assessed by CT or MRI. Patients with bone-only disease and blastic-only metastasis are not eligible. Tumor lesions previously irradiated or subjected to other loco regional therapy will only be deemed measurable if progression at the treated site after completion of therapy is clearly documented.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "8dab0893-04cb-40ca-989a-81bf3c570511",
            "name": "ECOG Performance Status",
            "text": "Eastern Cooperative Oncology Group (ECOG) performance status 0-1.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "9c1321e0-237d-49dc-9830-28d7f2f1f350",
            "name": "Adequate Organ and Marrow Function",
            "text": "Adequate organ and marrow function defined as follows: \n\nANC 1,500/mm3 (1.5 x 109/L);\n\nPlatelets 100,000/mm3 (100 x 109/L);\n\nHemoglobin 9 g/dL (90 g/L);\n\nSerum creatinine 1.5 x ULN or estimated creatinine clearance 60 ml/min as calculated using the method standard for the institution;\n\nTotal serum bilirubin 1.5 x ULN (<3ULN if Gilbert’s disease);\n\nAST and/or ALT 3 x ULN (5.0 x ULN if liver metastases present);",
            "instanceType": "EligibilityCriterionItem"
          }
        ],
        "studyInterventions": [
          {
            "id": "e0391fe3-505f-4957-a51f-7f94903e103c",
            "name": "Palbociclib",
            "type": {
              "id": "f63c549b-4457-4f79-b7fe-01517ffd186d",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "role": {
              "id": "ebec2907-6597-4641-9471-732474ac0967",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "PD-0332991, an orally active reversible inhibitor of Cyclin-Dependent Kinase (CDK) 4/6.",
            "productIds": [
              "988f91d1-e44b-4f07-b069-22428483fcf2"
            ],
            "administrationIds": [
              "9d95f57f-d127-45b1-9308-fb77d1dddc55"
            ]
          },
          {
            "id": "112d9265-4a77-453f-9728-96c3dc7cae00",
            "name": "Placebo",
            "type": {
              "id": "f525182f-7dbb-4767-a82a-f969fa0f47cf",
              "code": "C41132",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Placebo",
              "instanceType": "Code"
            },
            "role": {
              "id": "aca3d6fc-5ddf-4191-a9dd-99771af01125",
              "code": "C41132",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Placebo",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Placebo matching palbociclib.",
            "productIds": [
              "545a7aeb-2939-4d37-a25d-d2f853648f20"
            ],
            "administrationIds": [
              "928b3b0c-dcdc-4aa3-a54c-7b5ea8497ed8"
            ]
          },
          {
            "id": "b972ac0d-13b3-4bc5-b3a5-e28c6c19709f",
            "name": "Fulvestrant",
            "type": {
              "id": "30fff04f-7c7c-415f-abe8-c05650683644",
              "code": "C54127",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Background Therapy",
              "instanceType": "Code"
            },
            "role": {
              "id": "d18bb01f-87d2-42cc-9ec4-8fbff06a6761",
              "code": "C54127",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Background Therapy",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Faslodex®, a competitive estrogen receptor (ER) antagonist, administered to all patients in both treatment arms.",
            "productIds": [
              "ec14c460-d51f-4a27-ab5e-ee2bea4e7cbc"
            ],
            "administrationIds": [
              "a3de14eb-dd0a-4c55-b464-e20c31206152"
            ]
          },
          {
            "id": "f8df8e06-90c4-4ce7-bbd3-128827ff3c44",
            "name": "Goserelin",
            "type": {
              "id": "b00e73a2-b4bc-4c6c-9bca-6c594b2d5619",
              "code": "C54127",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Background Therapy",
              "instanceType": "Code"
            },
            "role": {
              "id": "e1841495-0e10-4435-b81c-6d2ca8829d2b",
              "code": "C54127",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Background Therapy",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Zoladex® or generic, a Luteinizing Hormone-Releasing Hormone (LHRH) agonist, administered to all pre- and peri-menopausal women in both treatment arms.",
            "productIds": [
              "4341fa14-e48b-4d09-809b-1b91b159eff7"
            ],
            "administrationIds": [
              "9747556d-5461-4522-b69d-7eddb1863683"
            ]
          }
        ],
        "administrableProducts": [
          {
            "id": "988f91d1-e44b-4f07-b069-22428483fcf2",
            "name": "Palbociclib",
            "administrableDoseForm": {
              "id": "a6e30a87-315b-47fc-b98c-d0e13866583f",
              "code": "C25158",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Capsule",
              "instanceType": "Code",
              "standardCode": {
                "id": "3e585feb-2695-4172-970e-c1498092d9a2",
                "code": "C25158",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Capsule",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "922529c9-352b-400d-ae5d-99967fdc4df8",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "125 mg",
            "substanceIds": [
              "0fcfb590-5365-4725-9107-805b4eb4faac"
            ],
            "manufacturer": "Pfizer"
          },
          {
            "id": "545a7aeb-2939-4d37-a25d-d2f853648f20",
            "name": "Placebo",
            "administrableDoseForm": {
              "id": "83d38663-baf7-400b-8828-1fe960fccd5b",
              "code": "C25158",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Capsule",
              "instanceType": "Code",
              "standardCode": {
                "id": "0acc5759-6891-4e3b-8eae-93941e375cb8",
                "code": "C25158",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Capsule",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "cbdb171b-a0aa-4bc3-bb66-f2b19795a295",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "Matching 125 mg",
            "substanceIds": [
              "6b41e680-2764-4eb3-95af-0b02bd3c6ccb"
            ],
            "manufacturer": "Pfizer"
          },
          {
            "id": "ec14c460-d51f-4a27-ab5e-ee2bea4e7cbc",
            "name": "Fulvestrant (Faslodex®)",
            "administrableDoseForm": {
              "id": "15b03cf6-5e59-4d40-b711-4c86d725ea7f",
              "code": "C42945",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Injection",
              "instanceType": "Code",
              "standardCode": {
                "id": "df82b49c-45cc-4af9-b11a-8ea5c667b4ad",
                "code": "C42945",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Injection",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "03c53857-a0c8-4706-9aaf-7aab26f3ef05",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "500 mg",
            "substanceIds": [
              "3b60252f-203b-43e2-b055-f0dd81692473"
            ]
          },
          {
            "id": "4341fa14-e48b-4d09-809b-1b91b159eff7",
            "name": "Goserelin (Zoladex®)",
            "administrableDoseForm": {
              "id": "7f52b51d-7c7b-49cc-b386-bc0ff5b0282e",
              "code": "C17998",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Unknown",
              "instanceType": "Code",
              "standardCode": {
                "id": "ca4a4dbe-c07b-4dfa-964b-2881072d892b",
                "code": "C17998",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Unknown",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "adcda177-6b15-4d77-b702-1073cf4a36a4",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "3.6 mg"
          }
        ],
        "narrativeContentItems": [
          {
            "id": "33603fb0-68a5-44cf-9214-b335ba411d59",
            "name": "Study Objectives",
            "text": "Study Objectives",
            "order": 0,
            "instanceType": "NarrativeContent",
            "sectionNumber": "2",
            "sectionTitle": "Study Objectives",
            "sectionType": {
              "id": "118c0b47-e6a3-400e-8e51-a4dbf53a844f",
              "code": "Objectives",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Objectives",
              "instanceType": "Code"
            },
            "childIds": [
              "fd23168e-9d15-4b56-89b2-561444debccb"
            ]
          },
          {
            "id": "923fea54-2176-4ff8-ae28-c0595249003d",
            "name": "Treatment",
            "text": "Treatment",
            "order": 1,
            "instanceType": "NarrativeContent",
            "sectionNumber": "5",
            "sectionTitle": "Treatment",
            "sectionType": {
              "id": "aba4d7cf-7488-48b0-869c-cdc76aa31538",
              "code": "Treatment",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Treatment",
              "instanceType": "Code"
            },
            "childIds": [
              "31c72062-49e0-4ef0-a642-93306eed5804",
              "713e6c74-d510-4fd4-869d-057d55802ce4",
              "1164aec6-8d2c-4dbd-95da-e4b3387ea232"
            ]
          },
          {
            "id": "c44eadbb-6353-4ffe-b4a6-28054090840c",
            "name": "Assessments",
            "text": "Assessments",
            "order": 2,
            "instanceType": "NarrativeContent",
            "sectionNumber": "6",
            "sectionTitle": "Assessments",
            "sectionType": {
              "id": "813eadec-597b-45a6-b8a0-ebe6e2ae7d1f",
              "code": "Assessments",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Assessments",
              "instanceType": "Code"
            },
            "childIds": [
              "48b3dfa5-be91-4c03-ab38-858b6938eb1e",
              "22675663-8bba-4381-b480-2b061f3a002a"
            ]
          },
          {
            "id": "9893dbbb-8250-4f2b-9006-0c07a911ebd1",
            "name": "Study Procedures",
            "text": "Study Procedures",
            "order": 3,
            "instanceType": "NarrativeContent",
            "sectionNumber": "7",
            "sectionTitle": "Study Procedures",
            "sectionType": {
              "id": "8177ca60-562b-4ca6-be6c-fedb071beeb4",
              "code": "Study Procedures",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Procedures",
              "instanceType": "Code"
            },
            "childIds": [
              "66c00d48-333e-4af0-9c9d-860632d5506f",
              "8a27d1dc-0934-4d2c-afd7-a3673233b589",
              "376a1fb3-a227-4380-87c9-3094ff82592e"
            ]
          }
        ],
        "abbreviations": [
          {
            "id": "db26926b-5d55-4d6a-855d-3c220bef629a",
            "abbreviatedText": "PRO",
            "expandedText": "Patient-Reported Outcome",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2c120bfa-1cfc-43dc-9973-f40bf73d2215",
            "abbreviatedText": "PFS",
            "expandedText": "Progression Free Survival",
            "instanceType": "Abbreviation"
          },
          {
            "id": "8818bc7a-b5e5-4060-97fc-667c04918ac4",
            "abbreviatedText": "CRF",
            "expandedText": "Case Report Form",
            "instanceType": "Abbreviation"
          },
          {
            "id": "d7eadb4b-f69b-40d7-ba7e-1fc2462b583c",
            "abbreviatedText": "HbA1c",
            "expandedText": "hemoglobin A1c",
            "instanceType": "Abbreviation"
          },
          {
            "id": "6713eb8a-f35e-40dc-8fdc-d29adec8b6c2",
            "abbreviatedText": "RECIST",
            "expandedText": "Response Evaluation Criteria in Solid Tumors",
            "instanceType": "Abbreviation"
          },
          {
            "id": "e39620ce-19df-4fe8-8672-0a804a1e2c39",
            "abbreviatedText": "CYP3A",
            "expandedText": "Cytochrome P450 3A",
            "instanceType": "Abbreviation"
          },
          {
            "id": "c262ec34-719a-4ca3-b5a4-85c312de62b8",
            "abbreviatedText": "CDK",
            "expandedText": "Cyclin-Dependent Kinase",
            "instanceType": "Abbreviation"
          },
          {
            "id": "f12c00d4-0701-40b2-8a17-417cae86dd9b",
            "abbreviatedText": "DNA",
            "expandedText": "Deoxyribonucleic Acid",
            "instanceType": "Abbreviation"
          },
          {
            "id": "84514371-7363-4885-93ca-41fffedacc7e",
            "abbreviatedText": "ER",
            "expandedText": "Estrogen Receptor",
            "instanceType": "Abbreviation"
          },
          {
            "id": "e4e6dbce-af46-48ef-9098-ba7fd5a2cd7a",
            "abbreviatedText": "AI",
            "expandedText": "aromatase inhibitor",
            "instanceType": "Abbreviation"
          },
          {
            "id": "008c2440-c2e2-4bd7-bde8-84ba650ef6ac",
            "abbreviatedText": "HR",
            "expandedText": "hormone receptor",
            "instanceType": "Abbreviation"
          },
          {
            "id": "b95218e4-f504-4a04-98ee-8ba0eddeafd4",
            "abbreviatedText": "HER2",
            "expandedText": "Human Epidermal Growth Factor Receptor 2",
            "instanceType": "Abbreviation"
          },
          {
            "id": "a360b9b3-c136-4e45-b497-d9efdd93391e",
            "abbreviatedText": "HR",
            "expandedText": "Hazard Ratio",
            "instanceType": "Abbreviation"
          },
          {
            "id": "3b0f3e4f-0b53-4190-9755-93be68555d6c",
            "abbreviatedText": "CI",
            "expandedText": "confidence interval",
            "instanceType": "Abbreviation"
          }
        ],
        "amendments": [
          {
            "id": "a6315534-d135-4ba0-aeab-df5d74b05b31",
            "number": "3",
            "name": "Amendment 3",
            "scope": {
              "id": "71998e02-0017-4b78-97f9-458d7c0ee7f5",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "0c9ac061-13e4-41f2-a4c1-8c4309bebb25",
              "code": {
                "id": "4479bc90-0ed5-4731-aa51-da4f4254480c",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "25cdd738-81ee-41ef-b904-35a22dc1971e",
                "type": {
                  "id": "886c527a-4b11-40d8-910e-347bf5590c81",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Upon approval, some of the safety and efficacy assessments will be reduced due to: 1) completion of efficacy analyses including interim and final analysis of primary endpoint and secondary endpoints; 2) additional analyses of safety conducted to comply with Health Authorities requirements; 3) at the time of amendment approval a smaller number of patients will be on study treatment and patients will remain under observation for a follow-up period of approximately 1 year and a half.",
            "effectiveDate": "2015-10-20",
            "reasonIds": [
              "cebc69bd-07d1-4255-b1d8-7f7640de5148",
              "c2165a13-68f9-41fb-b26b-da7374ccb3f6"
            ],
            "previousVersion": "2",
            "newVersion": "3"
          },
          {
            "id": "cb0d9b41-cc0e-4149-aa68-c83c5b54a0e6",
            "number": "2",
            "name": "Amendment 2",
            "scope": {
              "id": "c9196842-c1bb-4968-8422-3f72f9216c34",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "e17f97a0-c60f-4705-bbb3-764adfadff50",
              "code": {
                "id": "843253d3-104b-49eb-b6df-f2aa2569a1c3",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "2eb893e6-3e22-4dd9-b91c-828bea33dcf4",
                "type": {
                  "id": "3c277828-bb8f-4fc1-bc7d-7a400baaaa6e",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "This amendment added prospective monitoring of hemoglobin A1c to characterize effects on glucose metabolism, updated human pharmacokinetic data to support administration with food, prohibited concomitant use of proton-pump inhibitors and strong/moderate CYP3A inducers/inhibitors, and refined criteria for treatment restart after toxicity.",
            "effectiveDate": "2014-09-30",
            "reasonIds": [
              "f73ba9bd-c210-4dd8-b168-dd0c65389cc3",
              "8cec93fc-e12e-482c-bb6d-1532aae3fd00",
              "69724b58-b728-4ed0-a02a-461c71a02fa4"
            ],
            "previousVersion": "1",
            "newVersion": "2"
          },
          {
            "id": "4f26dd79-eb5d-4b00-9ff8-5615d4850fa3",
            "number": "1",
            "name": "Amendment 1",
            "scope": {
              "id": "1c9c1936-0006-44f4-bc2c-2ed3e379967a",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "c20b112f-d86a-48c5-aad4-254babedcdee",
              "code": {
                "id": "50a3ee9f-4db2-48a1-9ede-8843609a89c6",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "367ebbb1-6ce9-495b-b887-b7cb7ec19632",
                "type": {
                  "id": "7855eaec-0dd4-4765-bf18-cd9ef52e511d",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "This amendment added ocular safety assessment procedures to assess the potential risk of palbociclib-associated lens changes, incorporated preliminary results from clinical pharmacology studies to recommend taking palbociclib with food and prohibit proton-pump inhibitors, and clarified inclusion/exclusion criteria to address frequent questions from investigational sites.",
            "effectiveDate": "2014-04-04",
            "reasonIds": [
              "94875fd4-4670-4054-990a-2acdac6ae6ae",
              "c51b2e83-ec9d-453e-a88f-1ee4f85b351e",
              "0e987f5d-b66e-4ab9-b9bb-1a07b9fa33e9"
            ],
            "previousVersion": "Original protocol",
            "newVersion": "1"
          }
        ],
        "medicalDevices": [
          {
            "id": "ac3ae9fc-1ea0-42ce-8b8f-7db23aff18a9",
            "name": "Computed Tomography Scanner",
            "instanceType": "MedicalDevice",
            "label": "CT Scanner",
            "description": "Device used to perform CT scans of the chest, abdomen, and pelvis for tumor assessment.",
            "deviceType": {
              "id": "9643317e-e477-476a-ace1-5f357edea081",
              "code": "Diagnostic Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Diagnostic Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "aea0f9ae-e8fd-4610-ba84-cd2815a798aa",
            "name": "Magnetic Resonance Imaging Scanner",
            "instanceType": "MedicalDevice",
            "label": "MRI Scanner",
            "description": "Device used to perform MRI scans of the chest, abdomen, and pelvis for tumor assessment.",
            "deviceType": {
              "id": "cc06186c-bc3c-4e3a-ba28-6b46c02cac62",
              "code": "Diagnostic Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Diagnostic Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "7844e865-528c-4af7-9ab9-29999dec0086",
            "name": "Electrocardiograph Machine",
            "instanceType": "MedicalDevice",
            "label": "ECG Machine",
            "description": "Device used to perform 12-lead electrocardiograms.",
            "deviceType": {
              "id": "552f3d74-104b-4f39-8f59-0c39720a4664",
              "code": "Diagnostic Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Diagnostic Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "10f6cd97-1f33-4c97-9302-f8f7120ccce3",
            "name": "Radionuclide Bone Scanner",
            "instanceType": "MedicalDevice",
            "label": "Bone Scanner",
            "description": "Device used for whole body radionuclide bone scans.",
            "deviceType": {
              "id": "b44b1661-a0b7-407f-9ac4-ec20b5926b1d",
              "code": "Diagnostic Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Diagnostic Device",
              "instanceType": "Code"
            }
          }
        ],
        "conditions": [
          {
            "id": "fe3672c0-be22-4f61-8602-f94a0d4af72c",
            "name": "Fulvestrant Dosing Hold Criteria",
            "instanceType": "Condition",
            "description": "Condition under which fulvestrant should not be administered.",
            "text": "Fulvestrant should not be administered if the platelet count is <50,000/mm3."
          },
          {
            "id": "a8e7d706-360b-48f5-8901-689e79853cf3",
            "name": "Palbociclib Retreatment Criteria",
            "instanceType": "Condition",
            "description": "Criteria that must be met before resuming palbociclib/placebo after an interruption or at the start of a new cycle.",
            "text": "Platelet count >=50,000/mm3; ANC >=1000/mm3 and no fever; Grade >=3 non-hematologic AEs recovered to Grade <=1 or baseline; QTc <=500 msec."
          },
          {
            "id": "5f385edc-a403-41c8-883d-680729e88cba",
            "name": "Palbociclib Dose Reduction Trigger",
            "instanceType": "Condition",
            "description": "Toxicity criteria that trigger a dose reduction for subsequent cycles.",
            "text": "In case of a Grade 2 toxicity lasting for >3 weeks or a Grade >=3 toxicity (both assessed in the presence of maximum supportive care as judged by the investigator), dose reduction is recommended for the subsequent cycles."
          },
          {
            "id": "3fd10afe-b983-46a9-baec-de4748371a87",
            "name": "Sensitivity to Prior Hormonal Therapy Definition",
            "instanceType": "Condition",
            "description": "Definition used for patient stratification.",
            "text": "Sensitivity to prior hormonal therapy is defined as either: (i) Documented clinical benefit (CR, PR, SD >=24 weeks) to at least one prior hormonal therapy in the metastatic setting, OR (ii) At least 24 months of adjuvant hormonal therapy prior to recurrence."
          },
          {
            "id": "1d83c1d3-e8f3-4e6a-8776-39ee76718389",
            "name": "Progression on Prior Endocrine Therapy",
            "instanceType": "Condition",
            "description": "Eligibility criterion related to disease progression on prior therapy.",
            "text": "disease has progressed during or within 12 months of completion of adjuvant therapy... or progressed while on, or within 1 month after the end of prior therapy for advanced/metastatic breast cancer"
          },
          {
            "id": "889006bb-38d1-45c1-9cee-7465fa02ef44",
            "name": "E-DMC Safety Review Trigger",
            "instanceType": "Condition",
            "description": "Condition for the external data monitoring committee to perform an early safety review.",
            "text": "An external data monitoring committee (E-DMC) will perform an early review of safety data from approximately the first 40 randomized patients with sufficient pharmacokinetic (PK) sampling to confirm safety and tolerability of the combination."
          }
        ],
        "administrations": [
          {
            "id": "61f85665-25ad-43b3-b0b5-5b300c051775",
            "name": "Administration of RECIST version",
            "description": "RouteOfAdministration.ORAL DosingFrequency.ONCE_DAILY",
            "instanceType": "Administration",
            "route": {
              "id": "01330821-7592-46b2-9b80-18bfd7fa501d",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Oral",
              "instanceType": "Code"
            }
          }
        ],
        "rationale": "Protocol version"
      }
    ],
    "name": "MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX) WITH OR WITHOUT PD-0332991 (PALBOCICLIB) GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY"
  },
  "administrations": [
    {
      "id": "9d95f57f-d127-45b1-9308-fb77d1dddc55",
      "name": "Palbociclib 125 mg",
      "instanceType": "Administration",
      "dose": "125 mg",
      "doseFrequency": "once daily on Days 1 to 21 of each 28-day cycle (3 weeks on, 1 week off)",
      "route": {
        "id": "80c0c06a-eb25-402c-8a78-f784abbc9448",
        "code": "Oral",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Oral",
        "instanceType": "Code"
      },
      "duration": "Until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent."
    },
    {
      "id": "928b3b0c-dcdc-4aa3-a54c-7b5ea8497ed8",
      "name": "Placebo",
      "instanceType": "Administration",
      "dose": "Matching placebo",
      "doseFrequency": "once daily on Days 1 to 21 of each 28-day cycle (3 weeks on, 1 week off)",
      "route": {
        "id": "9f666008-9528-4207-8333-415d19386c43",
        "code": "Oral",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Oral",
        "instanceType": "Code"
      },
      "duration": "Until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent."
    },
    {
      "id": "a3de14eb-dd0a-4c55-b464-e20c31206152",
      "name": "Fulvestrant 500 mg",
      "instanceType": "Administration",
      "dose": "500 mg",
      "doseFrequency": "On Days 1 and 15 of Cycle 1, then every 28 days thereafter.",
      "route": {
        "id": "3a3c122c-e4e2-4570-b62b-9b9719129ce8",
        "code": "Intramuscular",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intramuscular",
        "instanceType": "Code"
      },
      "duration": "Until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent."
    },
    {
      "id": "9747556d-5461-4522-b69d-7eddb1863683",
      "name": "Goserelin 3.6 mg",
      "instanceType": "Administration",
      "dose": "3.6 mg",
      "doseFrequency": "every 28 days",
      "route": {
        "id": "1a67dfc4-540d-44dc-9744-a06ee71d946d",
        "code": "Subcutaneous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Subcutaneous",
        "instanceType": "Code"
      },
      "duration": "For the duration of the trial for pre- and peri-menopausal women. Must be started at least 4 weeks prior to randomization."
    }
  ],
  "substances": [
    {
      "id": "0fcfb590-5365-4725-9107-805b4eb4faac",
      "name": "Palbociclib",
      "instanceType": "Substance",
      "description": "PD-0332991"
    },
    {
      "id": "6b41e680-2764-4eb3-95af-0b02bd3c6ccb",
      "name": "Fulvestrant",
      "instanceType": "Substance"
    },
    {
      "id": "3b60252f-203b-43e2-b055-f0dd81692473",
      "name": "Goserelin",
      "instanceType": "Substance"
    }
  ],
  "studyDefinitionDocument": {
    "id": "4ed96b59-a1ab-4dfc-942a-9dd13a0569ef",
    "name": "PD-0332991 (Palbociclib) A5481023 (PALOMA-3)",
    "documentType": "Protocol",
    "language": "en",
    "instanceType": "StudyDefinitionDocument",
    "version": "3",
    "versionDate": "2015-10-20",
    "contentIds": [
      "33603fb0-68a5-44cf-9214-b335ba411d59",
      "923fea54-2176-4ff8-ae28-c0595249003d",
      "c44eadbb-6353-4ffe-b4a6-28054090840c",
      "9893dbbb-8250-4f2b-9006-0c07a911ebd1"
    ]
  },
  "geographicScope": {
    "id": "6cac28f2-8ce7-4225-ae6c-17b3fa67ac6b",
    "name": "Study Geographic Scope",
    "scopeType": "International",
    "instanceType": "GeographicScope",
    "countryIds": [
      "eaa01b7d-8856-44d3-a657-3848b0623d9e"
    ],
    "regions": [
      "North America",
      "Europe"
    ]
  },
  "countries": [
    {
      "id": "eaa01b7d-8856-44d3-a657-3848b0623d9e",
      "name": "United States",
      "instanceType": "Country",
      "code": "US"
    }
  ],
  "ingredients": [
    {
      "id": "d03cc8a2-7e0e-492f-a06d-47fa6881dc34",
      "name": "Palbociclib",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "d4657ffa-72b0-484b-a149-96497033ab43"
    },
    {
      "id": "1b4cbec2-e8c6-4909-90dd-a31f49d0468f",
      "name": "Fulvestrant",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "038c546b-f17a-4947-8f79-eba29e1afcd0",
      "name": "Goserelin",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "4774b7f3-6e7e-425b-b33e-7e6d16e1c7ab",
      "name": "Placebo for Palbociclib",
      "role": "Inactive",
      "instanceType": "Ingredient"
    }
  ],
  "strengths": [
    {
      "id": "0e8f7a64-adbb-45bb-91ec-83c21236244e",
      "instanceType": "Strength",
      "value": 125,
      "unit": "mg",
      "numerator": {
        "value": 125,
        "unit": "mg"
      }
    },
    {
      "id": "990b6a8e-5055-43b5-9184-111e4c4a7bc6",
      "instanceType": "Strength",
      "value": 250,
      "unit": "mg",
      "numerator": {
        "value": 250,
        "unit": "mg"
      }
    },
    {
      "id": "c7eed431-1ffe-459a-bd42-9ebe543b48da",
      "instanceType": "Strength",
      "value": 500,
      "unit": "mg",
      "numerator": {
        "value": 500,
        "unit": "mg"
      }
    }
  ],
  "transitionRules": [
    {
      "id": "909e0b23-f71d-4086-a22b-070d48489977",
      "name": "Continuation Post-Progression",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "fromElementId": "af66afba-59ad-4412-b804-53b2259a25a8",
      "toElementId": "2cfbe314-72f5-42b4-ae44-460de57f6d76",
      "text": "Patients showing PD can continue with study treatment at the discretion of the investigator as long as that is considered to be in the best interest of the patient and no new anticancer treatment is initiated."
    },
    {
      "id": "6f13a81e-e0dd-47df-b7cf-65877a70d8a2",
      "name": "Partial Discontinuation for Toxicity",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "fromElementId": "221a9501-2acb-497c-984e-a31b11096b8c",
      "toElementId": "93948444-532a-4a5a-91c3-162ca58932b2",
      "text": "should palbociclib/placebo related toxicity mandate palbociclib/placebo discontinuation, patients can continue to receive fulvestrant alone."
    },
    {
      "id": "bed9d670-5eaa-4320-8b42-986e59f4de69",
      "name": "Transition to Follow-up Phase",
      "instanceType": "TransitionRule",
      "transitionType": "Epoch Transition",
      "fromElementId": "af66afba-59ad-4412-b804-53b2259a25a8",
      "toElementId": "4eecd545-1efe-4b50-82f9-5e4680650398",
      "text": "Patients discontinuing the active treatment phase (ie, discontinuing both palbociclib/placebo and fulvestrant) will enter a follow-up phase during which survival and new anti-cancer therapy information will be collected."
    },
    {
      "id": "98dad491-4bc3-43f6-88d8-431ea588ef6d",
      "name": "Fulvestrant Dose Delay",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "Treatment delay for fulvestrant-related toxicities will be performed as per the investigator’s best medical judgment, but by no more than 7 days."
    },
    {
      "id": "326e7b2c-b231-4b1b-b5b3-e5469b37d6cf",
      "name": "Fulvestrant Dose Skip",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "If delay of longer than 7 days is required then the dose should be skipped."
    },
    {
      "id": "ee0810e7-b0c7-49bd-83a9-f598f54ae037",
      "name": "Palbociclib Discontinuation for Delayed Recovery",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "If these parameters [retreatment criteria] have not been met after 3 weeks of dosing interruption, the patient should permanently discontinue palbociclib/placebo treatment."
    },
    {
      "id": "fa8e3c26-f341-4f85-93fb-faeede9ac09d",
      "name": "Palbociclib Dose Reduction",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "Dose reduction of palbociclib/placebo by one, and, if needed, by two dose levels is recommended depending on type and severity of the toxicity."
    },
    {
      "id": "8052fb2c-6175-4b8f-b4fc-a53c609060ba",
      "name": "Palbociclib Schedule Change",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "Patients requiring more than two dose reductions will be allowed to receive 75 mg/day for 2 weeks on followed by 2 weeks off study treatment."
    },
    {
      "id": "ebe81579-8539-4bae-bd5b-5e00a84aec01",
      "name": "No Dose Re-escalation",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "Once a dose has been reduced for a given patient, all subsequent cycles should be administered at that dose level... Dose re-escalation is not allowed."
    }
  ],
  "studySites": [
    {
      "id": "29df8f9a-ab4a-41a2-9612-edd704a43ca2",
      "name": "Memorial Sloan Kettering",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "201",
      "country": "United States"
    },
    {
      "id": "06e3aae9-f6a2-4527-aa5a-ff037945f910",
      "name": "MD Anderson Cancer Center",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "202",
      "country": "United States"
    },
    {
      "id": "b2522248-cc19-4a1f-a1d2-92d9252a84a4",
      "name": "Dana-Farber Cancer Institute",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "203",
      "country": "United States"
    },
    {
      "id": "ae554fcf-2c5d-4dd7-a357-a6ba5d305a09",
      "name": "UCLA Jonsson Comprehensive Cancer Center",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "204",
      "country": "United States"
    },
    {
      "id": "e66b1aac-6673-4d12-8756-124f14d2b5af",
      "name": "University of Chicago Medicine",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "205",
      "country": "United States"
    },
    {
      "id": "1b9108ad-d42d-4f7c-846e-cdd603bbc109",
      "name": "Sarah Cannon Research Institute",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "206",
      "country": "United States"
    },
    {
      "id": "bca11c8d-8050-405b-9278-0f0e6311cba2",
      "name": "Princess Margaret Cancer Centre",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "207",
      "country": "Canada"
    },
    {
      "id": "efcb3427-45b9-44b9-8538-04fff2765b85",
      "name": "Royal Marsden Hospital",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "208",
      "country": "United Kingdom"
    },
    {
      "id": "5e64b622-319e-440d-8b59-0f5ef9b7fa73",
      "name": "Institut Gustave Roussy",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "209",
      "country": "France"
    },
    {
      "id": "50895dc3-e210-43a2-837f-12a8a71ead0f",
      "name": "University Hospital Heidelberg",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "210",
      "country": "Germany"
    },
    {
      "id": "63c854c9-bbce-4f4d-9378-c6f3b1e4dc47",
      "name": "Netherlands Cancer Institute",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "211",
      "country": "Netherlands"
    },
    {
      "id": "22dfccf0-2faa-4e59-83a9-415e6d2598d6",
      "name": "Hospital Vall d'Hebron",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "212",
      "country": "Spain"
    },
    {
      "id": "1ffc3bae-8702-4a0c-aea3-8f9d6132be26",
      "name": "Peter MacCallum Cancer Centre",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "213",
      "country": "Australia"
    },
    {
      "id": "2a6edadd-69c1-4a53-a2eb-bd2f00515195",
      "name": "National Cancer Center Japan",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "214",
      "country": "Japan"
    },
    {
      "id": "b69f6008-c61e-4ac8-ab87-ed8b2fa0c492",
      "name": "Samsung Medical Center",
      "status": "Active",
      "instanceType": "StudySite",
      "siteNumber": "215",
      "country": "South Korea"
    }
  ],
  "studyRoles": [
    {
      "id": "da31d46a-9edc-4de7-978a-970d3440e54a",
      "roleCode": "Principal Investigator",
      "organizationId": "29df8f9a-ab4a-41a2-9612-edd704a43ca2",
      "instanceType": "StudyRole",
      "personId": "960348af-a2e5-4daf-a6ce-5154e085ee27"
    },
    {
      "id": "be11a7d6-b3cb-479b-8580-b3f9d1514451",
      "roleCode": "Principal Investigator",
      "organizationId": "06e3aae9-f6a2-4527-aa5a-ff037945f910",
      "instanceType": "StudyRole",
      "personId": "945c8c3c-a096-4554-b81f-a520c0413671"
    },
    {
      "id": "38b00814-b131-4922-856a-f9f4f81431a1",
      "roleCode": "Principal Investigator",
      "organizationId": "b2522248-cc19-4a1f-a1d2-92d9252a84a4",
      "instanceType": "StudyRole",
      "personId": "a4e3b7bf-ca9a-4622-aced-355ce90a48b3"
    },
    {
      "id": "163febc2-5163-4460-a5dd-8fd74eeae77b",
      "roleCode": "Principal Investigator",
      "organizationId": "ae554fcf-2c5d-4dd7-a357-a6ba5d305a09",
      "instanceType": "StudyRole",
      "personId": "72322a45-9879-4508-95c6-3dd803d1ad59"
    },
    {
      "id": "4811dd91-d5a6-43f7-a3cb-6bfdd434534f",
      "roleCode": "Principal Investigator",
      "organizationId": "e66b1aac-6673-4d12-8756-124f14d2b5af",
      "instanceType": "StudyRole",
      "personId": "594c3ad4-ccb7-405b-a853-0067ac614db6"
    },
    {
      "id": "38a809d3-e805-491c-abc5-f5abca4051fe",
      "roleCode": "Principal Investigator",
      "organizationId": "1b9108ad-d42d-4f7c-846e-cdd603bbc109",
      "instanceType": "StudyRole",
      "personId": "0e287553-dd9c-4782-97a0-a9d3161e42e4"
    },
    {
      "id": "d52d73db-7bf5-41e3-ba4e-a4e3e82f2f39",
      "roleCode": "Principal Investigator",
      "organizationId": "bca11c8d-8050-405b-9278-0f0e6311cba2",
      "instanceType": "StudyRole",
      "personId": "472eb853-941a-4955-89be-51c404bef69b"
    },
    {
      "id": "1a161909-1666-4486-8d8b-cc4da62f0ecb",
      "roleCode": "Principal Investigator",
      "organizationId": "efcb3427-45b9-44b9-8538-04fff2765b85",
      "instanceType": "StudyRole",
      "personId": "a80bf533-4b93-4e5a-bd3c-6d41a52fcc0b"
    },
    {
      "id": "30597546-c9b4-43f4-a572-84c4c9f2aac1",
      "roleCode": "Principal Investigator",
      "organizationId": "5e64b622-319e-440d-8b59-0f5ef9b7fa73",
      "instanceType": "StudyRole",
      "personId": "573d31e3-2296-4f1e-89c0-16761406ed85"
    },
    {
      "id": "611ca8d2-23db-49d9-9a91-f16c593eea14",
      "roleCode": "Principal Investigator",
      "organizationId": "50895dc3-e210-43a2-837f-12a8a71ead0f",
      "instanceType": "StudyRole",
      "personId": "edcca19b-fd28-4a3a-a6dc-1e4784df04fb"
    },
    {
      "id": "18ea71f8-43d1-4408-a794-40c94ac30239",
      "roleCode": "Principal Investigator",
      "organizationId": "63c854c9-bbce-4f4d-9378-c6f3b1e4dc47",
      "instanceType": "StudyRole",
      "personId": "0dd8ecad-4dfc-457a-b769-784379742678"
    },
    {
      "id": "ba94fc67-00ea-45a1-a2f4-474d4e5ed6cb",
      "roleCode": "Principal Investigator",
      "organizationId": "22dfccf0-2faa-4e59-83a9-415e6d2598d6",
      "instanceType": "StudyRole",
      "personId": "ddafa382-700f-4623-9345-57a6434cc1cf"
    },
    {
      "id": "9be5af98-66b3-4962-9b89-dd20ef8f201a",
      "roleCode": "Principal Investigator",
      "organizationId": "1ffc3bae-8702-4a0c-aea3-8f9d6132be26",
      "instanceType": "StudyRole",
      "personId": "cad6bfb8-f590-4d90-9bf7-0247d1202f83"
    },
    {
      "id": "e0993fda-60ff-4179-9da8-a09656801527",
      "roleCode": "Principal Investigator",
      "organizationId": "2a6edadd-69c1-4a53-a2eb-bd2f00515195",
      "instanceType": "StudyRole",
      "personId": "98f9ab1a-dbaa-46e9-98f5-7d7558b96da4"
    },
    {
      "id": "11be483f-979c-4c64-8dce-c40ef19504e8",
      "roleCode": "Principal Investigator",
      "organizationId": "b69f6008-c61e-4ac8-ab87-ed8b2fa0c492",
      "instanceType": "StudyRole",
      "personId": "a52dee7c-ddb3-4cb9-88b7-d5cf60422d3f"
    }
  ],
  "assignedPersons": [
    {
      "id": "960348af-a2e5-4daf-a6ce-5154e085ee27",
      "nameId": "365285f1-387b-43f8-8ca0-11fbebb72d65",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    },
    {
      "id": "945c8c3c-a096-4554-b81f-a520c0413671",
      "nameId": "ebb5bcce-94a6-4bbc-ba6f-801a3fb1a2c2",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    },
    {
      "id": "a4e3b7bf-ca9a-4622-aced-355ce90a48b3",
      "nameId": "e14c89a9-04bb-47cc-a3b4-ea1969b075b0",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    },
    {
      "id": "72322a45-9879-4508-95c6-3dd803d1ad59",
      "nameId": "eafb43b4-4534-4f20-a276-e0cdc8bba9ac",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    },
    {
      "id": "594c3ad4-ccb7-405b-a853-0067ac614db6",
      "nameId": "2c3b4f23-88ab-4843-962b-7d6ba3c48a6b",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    },
    {
      "id": "0e287553-dd9c-4782-97a0-a9d3161e42e4",
      "nameId": "b1b6b267-0a70-4f66-ab3c-301bd2b9e153",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    },
    {
      "id": "472eb853-941a-4955-89be-51c404bef69b",
      "nameId": "c6af6b63-88c9-4bb0-9fc2-77a75a31d0ef",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    },
    {
      "id": "a80bf533-4b93-4e5a-bd3c-6d41a52fcc0b",
      "nameId": "dabe1025-bd0e-4545-a97d-718f0683d77c",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    },
    {
      "id": "573d31e3-2296-4f1e-89c0-16761406ed85",
      "nameId": "0338f8f7-c326-4dea-866d-27aca27d27cf",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    },
    {
      "id": "edcca19b-fd28-4a3a-a6dc-1e4784df04fb",
      "nameId": "d187c34a-d5a5-4c5e-93b6-823226eed466",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    },
    {
      "id": "0dd8ecad-4dfc-457a-b769-784379742678",
      "nameId": "00bdee3f-95d9-4a2f-b0b5-57ab45bd3944",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    },
    {
      "id": "ddafa382-700f-4623-9345-57a6434cc1cf",
      "nameId": "cd427411-4d6c-4524-a962-77ae27048a5d",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    },
    {
      "id": "cad6bfb8-f590-4d90-9bf7-0247d1202f83",
      "nameId": "75b78c1a-38df-4c01-8d7f-ac74270b9322",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    },
    {
      "id": "98f9ab1a-dbaa-46e9-98f5-7d7558b96da4",
      "nameId": "4a5c73e4-05aa-4be4-a480-fabafe2fd619",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    },
    {
      "id": "a52dee7c-ddb3-4cb9-88b7-d5cf60422d3f",
      "nameId": "79dcd128-578c-4d0e-9695-056414cd9438",
      "role": "Principal Investigator",
      "instanceType": "AssignedPerson"
    }
  ],
  "documentContentReferences": [
    {
      "id": "d5763d02-449d-4515-ac49-5f39daad5368",
      "name": "Rationale for Amendment 3",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "1.2.4.3",
      "sectionTitle": "Rationale for Changes in Amendment 3",
      "description": "Reference from Document History to section explaining rationale for Amendment 3."
    },
    {
      "id": "7e72d4c4-8deb-4d06-90d0-50b27ef27996",
      "name": "Tumor Assessment Clarification",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "6.4/7.2.1",
      "sectionTitle": "Schedule of Activities/Tumor Assessments",
      "description": "Reference from Document History clarifying that tumor assessments will be conducted as per local practice after approval of Amendment 3."
    },
    {
      "id": "f3c40386-230f-4326-aa6f-a3a8dc75b54f",
      "name": "Tumor Assessment Flowchart Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.2",
      "sectionTitle": "Tumor Assessment Requirements Flow Chart",
      "description": "Reference from Document History clarifying changes to tumor assessment procedures post-Amendment 3, as detailed in the flowchart."
    },
    {
      "id": "a54807d2-5687-40b9-bca8-e07512640d4e",
      "name": "Prohibited Medications Clarification",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.5.1",
      "sectionTitle": "Prohibited Medications",
      "description": "Reference from Document History clarifying permitted medications for patients who discontinued palbociclib/placebo."
    },
    {
      "id": "eed2fad4-5ff1-482e-9858-f2a8dc4e0c22",
      "name": "Human PK Data Update",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "1.2.1.2",
      "sectionTitle": "Human Pharmacokinetic Data",
      "description": "Reference from Document History for Amendment 2 indicating an update to the PK data section."
    },
    {
      "id": "551b1bdb-62fb-443e-882c-d7d6a20da300",
      "name": "Table 3 Dose Modification Update",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.3.4.2.3",
      "sectionTitle": "Table 3",
      "description": "Reference from Document History for Amendment 2 noting added language to Table 3 regarding criteria for treatment restart."
    },
    {
      "id": "0d659769-8b0a-494f-a356-f76479065a2f",
      "name": "Ocular Safety Assessments",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "7.2.2",
      "sectionTitle": "Ocular Safety Assessments",
      "description": "Reference from Document History for Amendment 1 regarding the addition of ocular safety assessment procedures."
    },
    {
      "id": "2869d4a0-5fc9-4825-a0a9-2d7bbb91c4f1",
      "name": "Appendix 4 Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 4",
      "sectionTitle": "RECIST version 1.1 Guidelines",
      "description": "Reference from Document History for Amendment 1 noting alignment of terminology with RECIST version 1.1 guidelines in Appendix 4."
    },
    {
      "id": "e051284f-8595-49ca-9080-aee59e3efecf",
      "name": "Appendix 8 Addition",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 8",
      "sectionTitle": "Wisconsin Age-Related Eye Disease Study (AREDS) 2008 Clinical Lens Opacity Grading Procedure",
      "description": "Reference from Document History for Amendment 1 noting the addition of Appendix 8."
    },
    {
      "id": "d30c5381-4469-4b9c-9bb5-6fba5c173e6d",
      "name": "Schedule of Activities Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "N/A",
      "sectionTitle": "SCHEDULE OF ACTIVITIES",
      "description": "In-text reference to the SCHEDULE OF ACTIVITIES for details on routine safety relevant assessments."
    },
    {
      "id": "ca93c158-5df6-4161-be3f-72655857a45a",
      "name": "List of Tables",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "N/A",
      "sectionTitle": "LIST OF TABLES",
      "description": "Reference to the list of tables in the protocol, including Table 1, Table 2, Table 3, and Table 4."
    },
    {
      "id": "f9d296ae-405f-4863-90e5-243bd2706500",
      "name": "List of Appendices",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "N/A",
      "sectionTitle": "APPENDICES",
      "description": "Reference to the list of appendices, including Appendices 1, 2, 3, 4, and 8."
    },
    {
      "id": "fc8b9653-6069-47de-8981-a9441a39a942",
      "name": "Fulvestrant Data Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "1.2.1.8",
      "sectionTitle": "Interim Analysis Data from Phase 3 Study A5481023",
      "description": "In-text reference to Section 1.2.1.8 regarding Fulvestrant."
    }
  ],
  "commentAnnotations": [
    {
      "id": "824f76ef-d514-4096-8e97-c85e53e0f37f",
      "text": "Active Treatment Phase: Assessments should be performed prior to dosing on the visit day unless otherwise indicated. Acceptable time windows for performing each assessment are described in the column headers. No time window is to be considered for treatment schedule of palbociclib/placebo. One cycle consists of 28 days. A cycle could be longer than 28 days if persistent toxicity delays initiation of the subsequent cycle. Day 1 of any cycle visit should coincide with the day the palbociclib/placebo treatment begins. If there are delays due to toxicity, then the start of the next cycle visit will be delayed until the patient has recovered and can begin study treatment again. Fulvestrant injection will be given every 28 days (+/- 7 days) with the exception of Cycle 1 during which it will be administered on Days 1 and 15 (±2 days allowed according to the protocol visit time windows). Goserelin will be administered every 28 days (+/- number of days allowed according to the protocol visit time windows). The active treatment phase is ongoing as long as the patient is receiving both study drugs (ie, palbociclib/placebo and fulvestrant) or fulvestrant alone.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities",
      "pageNumber": 15
    },
    {
      "id": "acd8fbf6-7af0-4733-85a4-3ef46a4db33c",
      "text": "Cycle 1/Day 1: Blood chemistry, hematology, and physical examination not required if acceptable screening assessment is performed within 7 days prior to randomization.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities",
      "pageNumber": 15
    },
    {
      "id": "708f399c-190c-46d0-b65a-eaab9fa04ac2",
      "text": "End of Treatment/Withdrawal: Visit to be performed as soon as possible but no later than 4 weeks from the last dose of investigational products and prior to initiation of any new anticancer therapy. Obtain assessments if not completed during the previous 4 weeks on study.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities",
      "pageNumber": 15
    },
    {
      "id": "f413d665-2432-41c6-aa16-00ae66cf75ed",
      "text": "Post Treatment Follow-up: Patients who discontinue study treatment should be contacted 28 calendar days (±7 days) after discontinuation of study treatment (palbociclib/placebo or fulvestrant) to assess if there have been any new adverse events and/or any change to any previously reported adverse events. This follow-up should occur 28 calendar days (±7 days) regardless of any new anti-cancer therapy that may have started. Telephone contact is acceptable. Follow-up visits to assess survival status will be conducted every 3 months going forward after approval of Amendment 3. See table footnote s (Survival Follow-up) below.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities",
      "pageNumber": 15
    },
    {
      "id": "f73aa8b0-726f-4578-a657-0a60df1406d5",
      "text": "Informed Consent: Informed consent must be obtained prior to any protocol required assessments being performed (with the exception of certain imaging assessments if meeting the criteria defined in the Screening Section).",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities",
      "pageNumber": 15
    },
    {
      "id": "64105115-4a45-454f-85ee-2dcbda40c7ac",
      "text": "Ophthalmology Examinations: Upon approval of Amendment 1, newly enrolled lens grading evaluable patients will undergo an ophthalmic examination by an ophthalmologist at screening, during study treatment on Cycle 4 Day 1, on Cycle 7 Day 1, on Cycle 13 Day 1 (ie, after 3, 6 and 12 months), every 12 months thereafter (ie, Days 1 of Cycles 25, 37, etc.) and at the End of Treatment/Withdrawal visit. Additional ophthalmic examinations may be performed as clinically indicated. It is expected that a minimum of 100 evaluable patients will participate in these examinations. Sites will be informed once these examinations are no longer required for patients newly enrolled in this study. Refer to the Ocular Safety Assessments Section for further details. Upon approval of Amendment 3, ophthalmology tests will continue to be collected.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities",
      "pageNumber": 15
    },
    {
      "id": "8d9f3e3a-e28f-4861-8dfa-f35063b65ab7",
      "text": "Laboratory tests: Hematology includes hemoglobin, WBC, absolute neutrophil count, platelet count. Hematology tests must meet retreatment criteria prior to administering palbociclib Blood chemistry includes AST/ALT, alkaline phosphatase, sodium, potassium, magnesium, total calcium, total bilirubin, blood urea nitrogen (BUN) (or urea), serum creatinine, and albumin. Additional hematology/chemistries panels may be performed as clinically indicated. Upon approval of Amendment 3, hemoglobin A1c will be measured in all patients every 3 cycles (Day 1) going forward (C7D1, C10D1, C13D1, etc) and at the End of Treatment/Withdrawal visit. Pregnancy test (serum) at screening only for women of childbearing potential. Test may be repeated as per request of IRB/IECs or if required by local regulations. Serum estradiol and Follicle stimulating hormone (FSH) levels are analysed at screening to confirm postmenopausal status of women <60 years old and who have been amenorrheic for at least 12 consecutive months. Upon approval of Amendment 3, blood chemistry will be performed every 3 cycles (Day 1) going forward (C7D1, C10D1, C13D1, etc) and at the End of Treatment/Withdrawal visit. Hemoglobin A1c will be tested at the time of blood chemistry. If an adverse event occurs that mandates blood chemistry to be performed (eg, hepatic function abnormality), the additional laboratory data will be recorded in the CRF.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities",
      "pageNumber": 15
    },
    {
      "id": "0de2697e-360e-4c10-96af-389d4bca3657",
      "text": "CT/MRI Scans of Chest, Abdomen, Pelvis: Upon approval of Amendment 3, tumor assessments will be performed as per local practice. Refer to the tumor assessment requirement flowchart.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities",
      "pageNumber": 15
    },
    {
      "id": "b94dc003-bac2-4728-a206-7233a9ac90ae",
      "text": "Survival Follow-Up: Upon approval of Amendment 3, for patients who discontinue study treatment, survival data will be collected every 3 months going forward. Telephone contact is acceptable. During follow-up visits the following data will be recorded in the CRF: 1) start, stop and type of new anticancer therapy; 2) tumor response of new anticancer therapy; 3) date of progression of the disease during or after the new antitumor agent; 4) survival status.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities",
      "pageNumber": 15
    },
    {
      "id": "fa23a09c-fda2-4b88-9771-279a2d575f18",
      "text": "Screening scans must occur within 4 weeks (ie, 28 days) prior to randomization unless otherwise specified.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Tumor Assessment Requirements Flowchart",
      "pageNumber": 20
    },
    {
      "id": "5f947f7d-9c17-462a-b482-2af21b5a3f05",
      "text": "During treatment period, upon approval of Amendment 3: tumor assessment must be done according to local practice: if tumor assessments are scheduled as per the original protocol, upon approval of Amendment 3 they can be performed at a different schedule if this is common practice at that institution or it is recommended by the physician according to the patient’s clinical conditions. Selection of imaging studies will depend on treating physician and radiologist as per local practice. Upon approval of Amendment 3, RECIST 1.1 may be used to evaluate imaging assessments but will not be mandatory. Evaluation of imaging studies will be conducted as per the practice at the institution.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Tumor Assessment Requirements Flowchart",
      "pageNumber": 20
    }
  ],
  "studyDefinitionDocumentVersions": [
    {
      "id": "34e1dad2-dbe5-4787-8a86-37d404df6efa",
      "versionNumber": "3.0",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2015-10-20",
      "description": "Final Protocol Amendment 3, incorporating changes to reduce safety and efficacy assessments after meeting primary endpoint.",
      "amendmentNumber": "Amendment 3"
    },
    {
      "id": "8f2b4920-adca-4b8b-a7e2-9c1e1f80ca10",
      "versionNumber": "2.0",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2014-09-30",
      "description": "Protocol Amendment 2, incorporating prospective monitoring of hemoglobin A1c and updates to pharmacokinetic data.",
      "amendmentNumber": "Amendment 2"
    },
    {
      "id": "d9359e1c-6081-429b-9eb9-2af835a18c1a",
      "versionNumber": "1.0",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2014-04-04",
      "description": "Protocol Amendment 1, incorporating ocular safety assessments and changes to study drug administration instructions.",
      "amendmentNumber": "Amendment 1"
    },
    {
      "id": "e02da834-c70f-4bf6-b293-320053fce515",
      "versionNumber": "Original",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2013-07-24",
      "description": "Original protocol document."
    }
  ],
  "computationalExecution": {
    "ready": true,
    "supportedSystems": [
      "EDC",
      "ePRO",
      "CTMS",
      "RTSM"
    ],
    "validationStatus": "issues_found"
  }
}